Hepatocellular carcinoma metastasis–immune microenvironment crosstalk: emerging mechanisms and immunotherapy Authors: Wenlong Zhu, Yanjie Zhang, Runze Jiang, Li Wang, Jin Ding Published: 2026 ABSTRACT Hepatocellular carcinoma (HCC), the most prevalent type of liver cancer globally, imposes a heavy burden on global public health owing to its consistently high incidence and mortality rates. Owing to the characteristics of its tissue structure, HCC has a high propensity for metastasis. Unfortunately, most patients are diagnosed at the middle or advanced stage and present with metastasis. The occurrence of metastasis often indicates a severe deterioration of the condition and the loss of an opportunity for radical treatment. Thus, immunotherapy represented by immune checkpoint inhibitors (ICIs) has become the first-line treatment for patients with advanced metastasis. The tumor immune microenvironment (TIME), as the core immune component within tumors, has been confirmed to be significantly associated with metastasis through the complex crosstalk with suppressive immune cells. This crosstalk dynamically participates in the metastatic cascade of HCC, assisting tumors in completing invasion and diffusion. The goal of immunotherapy is to restore the function of exhausted immune cells in the TIME. However, the complex immunosuppressive microenvironment often weakens treatment responses, posing severe challenges to the application of immunotherapies. Accordingly, there is an urgent need to deeply investigate the crosstalk among diverse cell types within the immunosuppressive microenvironment and to systematically elucidate the impact of such intercellular crosstalk on the HCC metastasis as well as the response to immunotherapy, so as to improve the clinical benefit rate of immunotherapy for patients with metastatic HCC. This review focuses on the dual role of immune cells in HCC metastasis and the novel mechanisms by which they promote the HCC metastatic cascade. It systematically summarizes current therapeutic strategies targeting the immunosuppressive microenvironment to combat HCC metastasis. On this basis, it prospectively proposes the future development direction of immunotherapy, providing more effective guidance for the clinical diagnosis and treatment of patients with metastatic HCC. Background Liver hepatocellular carcinoma (LIHC) is a globally common malignant tumor. The latest data from the International Agency for Research on Cancer (IARC) indicate that LIHC ranks sixth in incidence and third in tumor-related mortality worldwide, imposing a severe social burden [1–3]. LIHC comprises several subtypes, with hepatocellular carcinoma (HCC) being the most prevalent, representing approximately 80% of all LIHC cases [4, 5]. Owing to unique histological characteristics, HCC is highly susceptible to early metastasis, which closely correlates with poor clinical prognosis. Autopsy results demonstrate that metastatic lesions are detected in 50–84.6% of patients with HCC. Typically, HCC preferentially develops intrahepatic dissemination, followed by subsequent extrahepatic metastasis [6–8]. Moreover, the majority of patients are diagnosed at the middle or advanced stage with metastasis, thus losing the opportunity for surgical treatment. Owing to tumor heterogeneity and individual differences, patients show heterogeneous responses to targeted therapy and immunotherapy, and only a limited proportion of individuals can obtain clinical benefits. During HCC progression, early metastasis predominantly manifests as intrahepatic metastases (IM), which frequently invade the portal vein and its branches to form tumor thrombi. Thrombus detachment further triggers multiple metastatic foci. Accumulating evidence has confirmed that IM possess unique immunogenomic features and specific tumor microenvironment (TME) [9, 10]. In addition, HCC also readily develops extrahepatic metastasis, primarily involving perihilar lymph nodes, lungs, bones, and adrenal glands [11–14], while rare small intestinal metastasis has also been sporadically reported in a few cases [15]. Notably, HCC metastasis is the leading cause of treatment failure and patient mortality. Metastatic onset usually indicates critical disease deterioration, and most affected patients are consequently ineligible for radical therapy [16]. The liver, as an immune organ, orchestrates the balance between immune tolerance and activation. A growing body of clinical and basic studies has verified that the distinctive immune microenvironment of the liver profoundly modulates the initiation and progression of HCC. The innate immune system performs real-time tumor immune surveillance, whereas the adaptive immune system, with stable immune memory function, specifically identifies and eliminates tumor-specific antigens [17]. Notably, chronic inflammation disrupts the homeostasis of the liver immune microenvironment [18]. The liver contains various types of immune cells that work together to maintain immune homeostasis. Among them, the most important are innate T lymphocytes, including natural killer (NK) cells and mucosal-associated invariant T (MAIT) cells, which play crucial roles in chronic inflammation and tissue repair [19]. In the pathogenesis of HCC, immune cells must balance dual roles, including eliminating malignant cells and repairing damaged hepatic tissue to sustain homeostasis [20]. Once immune homeostasis is persistently disordered, the risk of HCC malignant transformation will be significantly increased [21]. In China, hepatitis B virus (HBV) infection is an independent risk factor for HCC, and the liver’s intrinsic immune homeostasis serves as a key mechanism for controlling chronic HBV infection [22]. Nevertheless, HBV disrupts liver immune homeostasis through multiple pathways. Mechanistically, HBV inhibits NK cell expansion via exosome secretion, while stimulating the production of transforming growth factor-β (TGF-β) and interleukin 10 (IL-10) to upregulate the expression of inhibitory receptors (PD-1 and CD94) on NK cells [23, 24]. Additionally, Kupffer cells, the largest population of immune cells in the liver [25], promote CD8+ T cell exhaustion under HBV stimulation and play a crucial role in shaping an immune-tolerant microenvironment [26]. Liver fibrosis, a key pathological stage in the progression of chronic liver disease (CLD) globally, is well-established as an independent risk factor for HCC initiation and progression [27]. During the progression of the “inflammation–fibrosis–HCC” axis, Kupffer cells (KCs) and monocyte-derived macrophages (MoMφs) are educated by hepatic stellate cells (HSC) into an immunosuppressive phenotype, thereby facilitating HCC initiation [28]. Collectively, these findings indicate that pathological insults disrupt liver immune homeostasis, which in turn drives the progression and metastasis of HCC. Tumors are complex, dynamic biological ecosystems rather than simple malignant cell clusters. The tumor immune microenvironment (TIME) serves as a key immune-related component of tumor. Extensive evidence confirms that crosstalk among immunosuppressive cells within the TIME strongly drives HCC progression, recurrence, and metastasis [5, 29]. The latest research indicates that HCC with epithelial–mesenchymal transition (EMT) features exhibits an immune desert phenomenon, specifically characterized by a reduction in the infiltration of NK cells and CD8+ T cells, meaning a significant decrease in the proportion of antitumor effector cells [30]. T cells are dominant immune components in the TIME, with distinct subsets exerting opposing regulatory roles. For instance, regulatory CD4+ T (CD4+ Treg) and exhausted CD8+ T (CD8+ Tex) jointly reshape an immunosuppressive microenvironment to facilitate tumor immune evasion and accelerate HCC malignant progression and metastasis. Conversely, cytotoxic CD8+ T (CD8+ Tc), effector T cells, and NK cells exert antitumor effects by recognizing and eliminating tumor cells [31, 32]. In addition to immunosuppressive T cells, tumor-associated macrophages (TAMs) are pivotal drivers of HCC immune escape and immunotherapy resistance. M2 macrophage can suppress the activation of effector T cells by secreting a series of immunosuppressive cytokines and promote tumor progression and metastasis through angiogenesis and EMT, ultimately diminishing the effectiveness of immunotherapy [33]. Overall, immunotherapy for patients with HCC often leads to adverse reactions such as drug resistance, which could be ascribed to the intricate crosstalk between malignant tumor cells and immunosuppressive cells. Therefore, there is an urgent need to delve into the crosstalk among numerous cells within the immunosuppressive microenvironment and comprehensively understand the implications for the efficacy of immunotherapy. In this review, we delve into the dual roles of immune cells in the metastatic cascade and summarize the novel mechanisms by which immune cells promote HCC metastasis from the perspective of liver organ specificity. We also explore the mechanisms underlying tumor immune resistance during metastasis. Finally, we propose therapeutic strategies targeting the immune microenvironment to combat HCC metastasis and summarize the biomarkers related to metastasis, aiming to better guide clinical management of patients with HCC metastasis. The biological processes underlying HCC metastasis The specificities of HCC metastasis Tumor cells that enter the circulatory system are defined as circulating tumor cells (CTCs). Whether CTCs can adapt to the TIME of metastatic lesion determines whether tumors can form metastases in target organs. Owing to the characteristics of its tissue structure, HCC exhibits a high degree of organ-specific metastasis. The liver has a rich and intricate vascular system, which not only facilitates the generation of circulating tumor cells but also renders it prone to early intrahepatic dissemination, which is often one of the factors deteriorating the clinical outcomes of patients. Notably, autopsy data show that 50–84.6% of patients with HCC present metastatic lesions [6–8]. In the process of HCC metastasis, IM are most likely to develop in the early stages, which often infiltrates the portal vein and its branches, resulting in the formation of tumor thrombi. The detachment of these thrombi can induce multiple metastatic lesions within the liver. Substantial evidence indicates that IM exhibit distinct immunogenomic characteristics and unique TIME [9, 10]. Therefore, multiomics technologies are utilized to explore the characteristics of metastatic lesions and depict the immune microenvironment of metastatic lesions, thereby guiding the advancement of immunotherapy. In addition to IM, HCC often metastasizes extrahepatically. Common metastatic sites include lymph nodes, lungs, bones, and adrenal glands. Among them, the lung is the most common metastatic site, accounting for approximately 40–50% [11–14]. The reason for this might be that the lungs have a rich blood supply and a dense network of capillaries, which facilitates the colonization of CTCs. The metastasis pattern of HCC plays a decisive role in formulating subsequent treatment strategies and predicting patient prognosis. Therefore, organ-targeted immunotherapies can be further designed on the basis of the histological and immunological characteristics of distinct metastatic sites, which represents a personalized treatment strategy for patients with metastatic disease in the future. Differentiation of the origin of multifocal hepatocellular carcinoma (MHCC) Given that IM is a unique metastatic pattern of HCC, patients with MHCC are commonly encountered in clinical practice. Thus, differentiating between IM and multicentric occurrence (MO) is of critical importance. In terms of origin, IM and MO exhibit differences to varying degrees [34]. MO can be detected at an early stage, whereas IM typically completes metastasis prior to diagnosis. Imaging modalities, as pivotal tools for HCC diagnosis, play a key role in distinguishing IM from MO. Specifically, IM is often characterized by a relatively large primary tumor, accompanied by portal vein tumor thrombi (PVTT) and satellite nodules of varying sizes around the primary lesion, with consistent enhancement patterns across lesions. In contrast, MO lacks a clear spatial relationship and displays heterogeneous enhancement patterns [35]. Mounting evidence indicates that MHCC has a high tumor mutational burden (TMB), with marked intratumoral heterogeneity among multiple lesions. IM and MO also differ in their genetic susceptibility and evolutionary trajectories [9, 36, 37]. Advances in multiomics technologies have enabled deeper investigations into the TIME of MHCC. IM lesions show reduced infiltration of T cells, B cells, and dendritic cells (DC), with a predominance of CD4+ Treg and CD8+ Tex. Conversely, M2 macrophages are more abundant in IM than in MO lesions. Additionally, immune cells in MO lesions express higher levels of immunosuppressive receptors. These TIME differences provide novel insights into personalized therapy for MHCC [10]. Notably, the hepatic microbiota also influences the heterogeneity and pathogenesis of MHCC. A recent study identified a nine-bacterium biomarker panel that can distinguish IM from MO [38], offering novel insights for their differentiation. Furthermore, clonality analysis, as a core method for determining the origin of MHCC, is widely used in clinical practice. IM lesions share similar differentiation features with the primary tumor, whereas MO lesions exhibit significant inter-lesion differences in differentiation [39]. In summary, these diverse technologies provide novel strategies for differentiating the origin of MHCC, while also facilitating the development of personalized treatment for patients with MHCC. Metastatic cascade The metastasis of HCC represents an extraordinarily intricate and multistep biological process, hence it is termed the “metastatic cascade,” which delineates the complete sequence in which cancer cells detach from the primary tumor, disseminate to distant organs of the body, and ultimately form metastatic lesions [40]. This process encompasses the following pivotal steps: angiogenesis of the primary tumor, EMT, local infiltration and invasion, intravasation, survival in circulation, extravasation, formation of micrometastatic foci, and colonization (Fig. 1) [41, 42]. As an initial step, angiogenesis in the primary tumor lays a solid foundation for tumor cells to enter the bloodstream, and EMT refers to the process in which tumor epithelial cells lose their epithelial characteristics and gradually acquire mesenchymal properties. During this process, tumor epithelial cells lose intercellular junctions and the cytoskeleton is rearranged, endowing tumor epithelial cells with motility [43]. In the subsequent stage, tumor cells secrete various kinds of proteases to degrade the extracellular matrix (ECM) and basement membrane, initiating local infiltration and invasion. Subsequently, tumor cells traverse the endothelium of blood vessels or lymphatic vessels to complete the intravasation process and thus enter the circulatory system. Then, tumor cells have completed their transition to CTCs. CTCs encounter formidable survival challenges within the circulatory system, being subjected to a series of influences, including mechanical forces exerted by blood flow, surveillance by immune cells, and spontaneous apoptosis. The surviving CTCs, during their transit through the target organs, will once again secrete proteases to penetrate the vascular endothelium and basement membrane, thereby gaining entry into the target organs. Upon arriving in the new environment, tumor cells must surmount immune surveillance once more and adapt to the local microenvironment before they can complete the process of colonization, which subsequently leads to the formation of metastatic lesions [44]. The metastatic cascade appears to be an amplifying effect. However, it is extremely inefficient and exhibits organ specificity in reality. This also offers insights for guiding the clinical management of overcoming tumor metastasis. Specifically, HCC metastasis can be targeted by blocking critical steps in the metastatic cascade, such as inhibiting angiogenesis, suppressing EMT, and eradicating CTCs.Fig. 1The metastatic cascade process. The metastatic cascade is an intricate process that encompasses seven specific steps: angiogenesis, EMT, ECM degradation, intravasation, survival in circulation, extravasation, and colonization. At the primary lesion of HCC, tumor cells facilitate angiogenesis, undergo EMT, and degrade the ECM to facilitate intravasation into the circulation. Notably, tumor cells that have entered the circulation are referred to as CTCs. Then, CTCs are confronted with challenges, including hemodynamic shear stress, immune surveillance, and apoptosis. Only CTCs that successfully achieve immune evasion are able to infiltrate the metastatic lesion. Furthermore, tumor cells must achieve immune evasion once again within the metastatic lesion to facilitate colonization The metastatic cascade process. The metastatic cascade is an intricate process that encompasses seven specific steps: angiogenesis, EMT, ECM degradation, intravasation, survival in circulation, extravasation, and colonization. At the primary lesion of HCC, tumor cells facilitate angiogenesis, undergo EMT, and degrade the ECM to facilitate intravasation into the circulation. Notably, tumor cells that have entered the circulation are referred to as CTCs. Then, CTCs are confronted with challenges, including hemodynamic shear stress, immune surveillance, and apoptosis. Only CTCs that successfully achieve immune evasion are able to infiltrate the metastatic lesion. Furthermore, tumor cells must achieve immune evasion once again within the metastatic lesion to facilitate colonization The dual roles of immune cells in HCC metastasis Innate immune cells KCs and macrophages Macrophages, a vital component of innate immune cells, play a pivotal role in the TIME. It is noteworthy that macrophages, owing to their high degree of plasticity, can transform from the conventional M1 type to the M2 type. TAMs, also referred to as M2-type macrophages, perform anti-inflammatory functions and can participate in tissue remodeling and facilitate tumor growth [45]. TAMs can directly engage in the metastatic cascade by promoting angiogenesis, enhancing the invasiveness of primary tumors, and facilitating EMT. Additionally, they can indirectly drive metastasis by assisting tumor cells in establishing metastasis-permissive microenvironment [46]. In recent years, studies have indicated that TAMs play a pivotal role in promoting tumor immune evasion and resistance to immunotherapy. Consequently, they have emerged as a highly promising target in the field of tumor immunotherapy [47]. The infiltration of TAMs is strongly associated with metastasis and unfavorable clinical outcomes among patients with HCC [48]. Given that TAMs are typically differentiated from tissue-resident macrophages, KCs and MoMφs serve as the primary sources of TAMs in HCC [49]. Currently, the role of KCs in promoting HCC metastasis has gradually garnered attention, emerging as a critical regulator of HCC metastasis. Several studies have demonstrated that HCC cells can educate KCs to transdifferentiate into TAMs via exosome secretion. The transformed KCs then promote HCC metastasis by secreting interleukin-6 (IL-6), which concurrently activates the downstream JAK1–ACAP4 axis and EMT-related pathways (Fig. 2) [50]. Furthermore, KCs not only facilitate HCC metastasis but also extensively participate in the liver metastasis of other malignancies, highlighting their inherent prometastatic potential [51–53]. This further provides insights for subsequent research. Studies on liver metastasis of other cancers can be referenced to investigate whether similar mechanisms exist in IM of HCC.Fig. 2Innate immune cells in HCC metastasis. Innate immune cells include KCs, macrophages, neutrophils, MDSCs, and NK cells. KCs are the primary source of TAMs. They can promote EMT either by secreting IL-6 to activate the JAK1–ACAP4 pathway or by differentiating into TAMs that secrete TGF-β. Additionally, TREM1⁺ TAMs can secrete CCL7 to promote EMT, thereby facilitating metastasis. Moreover, tumor cells can secrete oxLDL to activate the TREM2–SYK–CEBPα pathway, promoting the conversion of TAMs to TREM1⁺ TAMs. TREM2⁺ TAMs not only inhibit CTLs but also promote HCC metastasis. HBV can secrete S100A9 to activate the RAGE/TLR4–ROS pathway, inducing TANs to generate large amounts of NETs. Additionally, acetyl-CoA can promote NET formation by secreting CXCL1. NETs can facilitate metastasis either by secreting MMPs to promote EMT or via the TLR4/9–COX2 pathway. MDSCs indirectly promote metastasis by inhibiting the functions of CTLs to reshape metastasis-permissive microenvironment. The specific mechanisms involve tumor cells secreting YTHDF2 to enhance m6A modification of the MYC gene and secreting SOX4 to promote MDSC recruitment. Furthermore, ETV5 can upregulate PD-L1 expression in tumor cells to assist immune evasion and promote PMN-MDSC recruitment, thereby shaping metastasis-permissive microenvironment and indirectly facilitating metastasis. As core antimetastatic cells, NK cells often undergo functional exhaustion owing to suppression by multiple immunosuppressive cells, leading to upregulation of immune checkpoints such as PD-1, TIM-3, and LAG-3. Additionally, CTCs interact with exhausted NK cells via the CD155–TIGIT axis to assist CTC immune evasion and promote metastasis Innate immune cells in HCC metastasis. Innate immune cells include KCs, macrophages, neutrophils, MDSCs, and NK cells. KCs are the primary source of TAMs. They can promote EMT either by secreting IL-6 to activate the JAK1–ACAP4 pathway or by differentiating into TAMs that secrete TGF-β. Additionally, TREM1⁺ TAMs can secrete CCL7 to promote EMT, thereby facilitating metastasis. Moreover, tumor cells can secrete oxLDL to activate the TREM2–SYK–CEBPα pathway, promoting the conversion of TAMs to TREM1⁺ TAMs. TREM2⁺ TAMs not only inhibit CTLs but also promote HCC metastasis. HBV can secrete S100A9 to activate the RAGE/TLR4–ROS pathway, inducing TANs to generate large amounts of NETs. Additionally, acetyl-CoA can promote NET formation by secreting CXCL1. NETs can facilitate metastasis either by secreting MMPs to promote EMT or via the TLR4/9–COX2 pathway. MDSCs indirectly promote metastasis by inhibiting the functions of CTLs to reshape metastasis-permissive microenvironment. The specific mechanisms involve tumor cells secreting YTHDF2 to enhance m6A modification of the MYC gene and secreting SOX4 to promote MDSC recruitment. Furthermore, ETV5 can upregulate PD-L1 expression in tumor cells to assist immune evasion and promote PMN-MDSC recruitment, thereby shaping metastasis-permissive microenvironment and indirectly facilitating metastasis. As core antimetastatic cells, NK cells often undergo functional exhaustion owing to suppression by multiple immunosuppressive cells, leading to upregulation of immune checkpoints such as PD-1, TIM-3, and LAG-3. Additionally, CTCs interact with exhausted NK cells via the CD155–TIGIT axis to assist CTC immune evasion and promote metastasis Exosomes secreted by TAMs are internalized by HCC cells and human umbilical vein endothelial cells (HUVECs), which promotes EMT, enhances vascular endothelial permeability, and facilitates angiogenesis. HCC cells that absorb exosomes, in turn, secrete more granulocyte–macrophage colony-stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein-1 (MCP-1), and interleukin-4 (IL-4), thereby recruiting TAMs to form a positive feedback loop that further deteriorates the local TIME [54]. Furthermore, TAMs endow tumor cells with more stemness characteristics through the secretion of transforming growth factor-β (TGF-β), thereby enhancing the capacity for EMT. Inhibiting the secretion of TGF-β by TAMs can reverse the EMT-promoting effect (Fig. 2) [55]. With the advancement of single-cell sequencing technology (scRNA-seq), the tumor microenvironment can be further dissected. TAMs can be more accurately subclassified into different subtypes. For instance, the oxidized low-density lipoprotein (oxLDL) secreted by HCC cells polarizes TREM2+ TAMs through the TREM2–SYK–CEBPα axis. The polarized TREM2+ TAMs secrete immunosuppressive factors to inhibit the function of CD8+ T cells, thereby shaping an immunosuppressive microenvironment, leading to immune resistance and poor prognosis in patients with HCC [56]. Furthermore, SPP1+ TAM can shape an immunosuppressive microenvironment by inhibiting the infiltration of CD8+ T cells, leading to immune resistance in patients with HCC, which can be reversed by SPP1 inhibitors [57]. In addition, studies have also demonstrated that TREM1 is highly expressed in metastatic tissues of HCC, and its expression level is positively correlated with the degree of TAM infiltration. Mechanistically, TREM1+ TAMs promote EMT-driven metastasis by secreting C–C motif chemokine ligand 7 (CCL7). The above conclusions based on transcriptomics need to be further verified in both in vitro and in vivo models in the future (Fig. 2) [58]. In the future, the subtypes of TAMs can be further refined by multiomics technology, and a unified classification criterion can be established to more effectively guide clinical treatment. Currently, studies on reversing the immunosuppressive microenvironment brought about by TAMs has also been initiated. The immunosuppressive microenvironment can be reversed by targeting the receptors of TAMs. AXL, a member of the TAM receptor family, is highly expressed in a variety of tumors and promotes tumor cell proliferation, invasion, and metastasis. In preclinical models, small-molecule kinase inhibitors targeting AXL have demonstrated promising antitumor potential [59]. Neutrophils Neutrophils, the most numerous cells in human blood, play a pivotal role in the immune system as well as in tumorigenesis and tumor progression. Tumor-associated neutrophils (TANs) exhibit dual functions in the microenvironment. On the basis of functional differences, TANs can be classified into antitumor N1-TANs and protumor N2-TANs. Specifically, N1-TANs exert potent antitumor effects by directly or indirectly lysing tumor cells. In contrast, N2-TANs are closely implicated in the malignant progression of HCC, including tumor growth, local invasion, and distant metastasis [60]. N2-TAN can be recruited and reprogrammed by tumor cells, thereby promoting tumor angiogenesis to maintain an immunosuppressive microenvironment and accelerate the metastasis of HCC [61, 62]. Activated N2-TANs release ultrastructural reticular architectures termed neutrophil extracellular traps (NETs), which exert critical modulatory effects on tumor initiation and metastasis [63]. NET-mediated cell trapping and migration are associated with EMT and ECM degradation induced by matrix metalloproteinases (MMPs) [64, 65]. Specifically, neutrophils isolated from patients with HCC with PVTT or extrahepatic metastasis can form more NETs. The increased NETs not only trap HCC cells but also induce cell survival and enhance invasion ability, which stimulates the metastatic potential of HCC and thereby promotes HCC IM [66, 67]. Furthermore, NETs primarily amplify inflammatory responses and concurrently impair antitumor immune competence. Such alterations enable HCC cells to evade immune surveillance and subsequently promote metastasis. Mechanistically, NET formation is strongly facilitated by HBV-mediated S100A9 elevation, which further activates the downstream RAGE/TLR4–ROS signaling axis to synergistically promote HCC metastasis. Thus, NETs hold promise as a biomarker for predicting extrahepatic metastasis in HBV-related HCC [68]. Moreover, NETs can activate the TLR4/9–COX2 signaling pathway to capture HCC cells and enhance their invasiveness, thereby stimulating the metastatic potential of HCC (Fig. 2) [66]. NETs can also be effectively induced by local metabolites within the TME. Studies have shown that high acetyl-CoA levels are considered a key metabolic feature of metastatic cancers. TANs are recruited by CXCL1, whose expression is upregulated following acetyl-CoA accumulation. These recruited TANs subsequently trigger robust NET formation and further promote HCC metastasis [69]. In conclusion, TANs play a crucial role in facilitating the HCC metastasis through the release of NETs. Interrupting either the formation of NETs or the associated signaling pathways may counteract their functions, thereby providing valuable insights for the clinical therapies of patients with HCC metastasis [70]. Myeloid-derived suppressor cells (MDSC) MDSCs are precursors of mature monocytes, dendritic cells, and granulocytes. As suppressive immune cells, MDSCs have been demonstrated to be associated with immunosuppression, as well as tumor progression and metastasis [71, 72]. Owing to their high enrichment in the tumor immunosuppressive microenvironment and robust proliferative capacity, MDSCs have emerged as an evaluation indicator for the efficacy of tumor radiotherapy [73]. In the TIME, MDSCs predominantly facilitate tumor progression and metastasis by inhibiting the functions of CD8+ T cells and NK cells and promoting microvascular invasion [74]. Currently, studies have indicated that MDSC infiltration in the TIME is significantly elevated in response to SRY-box transcription factor 4 (SOX4) secreted by HCC cells. Recruited MDSCs further recruit FOXP3+ Tregs and suppress CD8+ T cells to shape metastasis-permissive microenvironment [75]. In addition, ETV5 promotes HCC metastasis and immune evasion by recruiting polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and enhancing their immunosuppressive capacity. These PMN-MDSCs further reduce CD8+ T cell infiltration to form metastasis-permissive microenvironment [76]. Furthermore, YTHDF2 stabilizes the messenger RNA (mRNA) of MYC through m6A modification, thereby promoting MDSCs to inhibit the cytotoxicity of CD8+ T cells. This process shapes a metastasis-permissive microenvironment and subsequently facilitates HCC metastasis (Fig. 2) [77]. Moreover, microvascular invasion represents another mechanism through which MDSCs facilitate metastasis. Specifically, HOXB5 recruits MDSCs by activating the CXCL1/CXCR2 axis, thereby enabling MDSCs to assist tumor cells in achieving local microvascular invasion [78]. Similarly, SLC7A2 recruits MDSCs via activation of the PI3K/Akt/NF-κB axis, which also allows MDSCs to exert their microvascular invasion function and promote local infiltration of tumor cells [74]. At present, corresponding studies have been conducted on reversing the immunosuppression induced by MDSCs. As a crucial component of tumor-infiltrating myeloid cells (TIMs), MDSCs highly express signal regulatory protein α (SIRPα). Blocking the CD47–SIRPα axis can effectively reverse the immunosuppressive function of MDSCs and simultaneously increases the infiltration of CD8+ T cells, which impedes the progression and metastasis of HCC [79]. Interestingly, the applications of novel nanomaterials in the treatment of HCC are also rather extensive. By targeting the ATP–adenosine metabolic pathway, both tumor cells and MDSCs can be simultaneously eliminated, thereby inhibiting the progression of primary tumors and distant metastasis [80]. NK cells NK cells have the distinctive capacity to recognize and eliminate tumor cells. Additionally, they can secrete a variety of cytokines to interact with T cells, B cells and DCs. Thus, NK cells serve as the central force in counteracting metastasis within the TIME [81]. The proportion of NK cells in tumor infiltration and circulation is positively correlated with the survival benefits of patients with HCC [82]. Nonetheless, NK cells still face the issue of functional exhaustion within the TIME, mainly manifested as downregulation of activating receptors, reduced secretion of cytokines, and weakened tumor-elimination capacity. NK cells are regulated by a variety of cells within the TIME. One aspect is that NK cells are inhibited by numerous immunosuppressive cells, such as MDSCs. Another is that NK cells are remodeled by tumor cells, thereby resulting in their functional dysregulation [83]. Furthermore, the upregulation of inhibitory receptors, such as PD-1, TIM-3, and LAG-3, further exacerbates NK cell exhaustion [84]. Therefore, whether NK cells can function normally determines their role in metastasis. A latest study has shown that splenic invariant natural killer T (iNKT) cells can significantly inhibit HCC IM. In the HCC metastasis model, the absence of iNKT leads to a decrease in the number and percentage of CD4+ T cells, indicating that the interaction between iNKT and CD4+ T cells plays a role in restricting splenic metastasis of HCC [85]. In addition, platelets can assist CTCs in evading NK cell-mediated innate immune surveillance in the circulatory system through the immune checkpoint CD155–TIGIT, which undoubtedly promotes the metastatic cascade. Blocking the CD155–TIGIT interaction with TIGIT antibodies restores NK cell immune surveillance of CTCs and significantly inhibits HCC metastasis (Fig. 2) [86]. Currently, NK-based therapies have emerged as a promising form of cell therapy for the treatment of solid tumors [87]. Chimeric antigen receptor (CAR)-engineered NK cells present a distinctive opportunity for generating CAR-NK cells that possess multiple specificities and fewer adverse effects [82], which has also improved the efficacy of immunotherapy to a certain extent. Nevertheless, overcoming immunosuppressive microenvironments remains a key unmet challenge for resolving drug resistance in future basic research and clinical translation. Adaptive immune cells B cells The abundance of B lymphocytes ranks second among tumor-infiltrating lymphocytes (TILs), which playing a crucial role in modulating immune responses and being of profound significance for the adaptive immunity against tumors [88, 89]. In combating HCC metastasis, B cells can not only directly differentiate into plasma cells to secrete antibodies that exert tumoricidal effects, but also assist other immune cells in eliminating tumor cells. Specifically, tumor-infiltrating B lymphocytes (TIL-B) manifest typical characteristics of B cells, including clonal expansion, antigen recognition, and differentiation into plasma cells for antibody production. The antibodies secreted by plasma cells can modulate the functions of antigenic targets on tumor cells, which allows macrophages to identify and phagocytose tumor cells. Alternatively, it can facilitate DCs in presenting tumor antigens and triggering the complement cascade. Moreover, it may also assist T and NK cells in exerting cytotoxic effects on tumor cells (Fig. 3) [90, 91]. During various stages of HCC, B cell infiltration occurs to varying extents, and their functions exhibit diverse degrees of divergence [89]. With the development of transcriptomics, the composition of the HCC TIME has been further analyzed at the single-cell level. In advanced HCC, the survival niche of B cells is usurped by tumor cells, leading to a notable decline in the number of B cells that execute tumor-elimination functions, which exacerbates the local immune microenvironment and promotes the metastasis of HCC [92, 93].Fig. 3Adaptive immune cells in HCC metastasis. Innate immune cells mainly include B cells and T cells. B cells play a dual role in HCC metastasis: TIL-Bs can not only directly differentiate into plasma cells to eliminate tumor cells but also enhance the AP capacity of DCs to boost the antitumor effect of NK cells. Additionally, naive B cells can differentiate into Bregs under the action of T PH cells. TAMs can also promote metastasis by secreting CXCL12 to bind to the CXCR4 receptor on Bregs. Moreover, tumor cells can induce Bregs to upregulate the TIM-1, thereby inhibiting the function of CD8+ Tc to reshape metastasis-permissive microenvironment to indirectly promote metastasis. T cells also exert a dual role in metastasis. HIF-1 can drive the conversion of CD8+ Tc to exhausted CD8+ Tex by recruiting TREM1+ TAMs. Lactate in the microenvironment and MDSCs can also promote this conversion process. CD8+ Tex mainly exert immunosuppressive functions by upregulating inhibitory receptors such as PD-1, TIM-3, and LAG-3. In contrast, tumor antigens can stimulate ChAT to enhance the antitumor effect of CD4+ T cells and downregulate the PD-1 on CD4+ T cells to inhibit metastasis. Notably, CD4+ Tn can be educated into CD4+ Tregs by TGF-β and IL-10 in the microenvironment, thereby inhibiting NK cells and activating CAFs to reshape metastasis-permissive microenvironment and indirectly promote metastasis. Additionally, CD8+ Tex can cooperate with TNFRSF4+ CD4+ Tregs and Ki67+ CD4+ Tregs to promote VETC formation, directly participating in the metastatic cascade Adaptive immune cells in HCC metastasis. Innate immune cells mainly include B cells and T cells. B cells play a dual role in HCC metastasis: TIL-Bs can not only directly differentiate into plasma cells to eliminate tumor cells but also enhance the AP capacity of DCs to boost the antitumor effect of NK cells. Additionally, naive B cells can differentiate into Bregs under the action of T PH cells. TAMs can also promote metastasis by secreting CXCL12 to bind to the CXCR4 receptor on Bregs. Moreover, tumor cells can induce Bregs to upregulate the TIM-1, thereby inhibiting the function of CD8+ Tc to reshape metastasis-permissive microenvironment to indirectly promote metastasis. T cells also exert a dual role in metastasis. HIF-1 can drive the conversion of CD8+ Tc to exhausted CD8+ Tex by recruiting TREM1+ TAMs. Lactate in the microenvironment and MDSCs can also promote this conversion process. CD8+ Tex mainly exert immunosuppressive functions by upregulating inhibitory receptors such as PD-1, TIM-3, and LAG-3. In contrast, tumor antigens can stimulate ChAT to enhance the antitumor effect of CD4+ T cells and downregulate the PD-1 on CD4+ T cells to inhibit metastasis. Notably, CD4+ Tn can be educated into CD4+ Tregs by TGF-β and IL-10 in the microenvironment, thereby inhibiting NK cells and activating CAFs to reshape metastasis-permissive microenvironment and indirectly promote metastasis. Additionally, CD8+ Tex can cooperate with TNFRSF4+ CD4+ Tregs and Ki67+ CD4+ Tregs to promote VETC formation, directly participating in the metastatic cascade Although most studies have demonstrated the direct or indirect antitumor effects of B cells, there is no direct evidence that B cells are involved in the HCC metastatic cascade [94]. Some studies have indicated that regulatory B cells (Bregs) can promote the progression of HCC and indirectly facilitate metastasis while shaping a locally immunosuppressive microenvironment [95]. Specifically, peripheral helper T (T PH) cells facilitate the differentiation of naive B cells into Bregs and collaboratively reshape the immunosuppressive microenvironment to facilitate HCC metastasis [96]. Furthermore, CXCL12+ TAMs recruit PD-L1+ Bregs via the CXCL12–CXCR4 axis, which acts synergistically to facilitate HCC metastasis [97]. Moreover, tumor cells can also secrete numerous exosomes to educate Bregs to highly express TIM-1. TIM-1+ Bregs exert a potent inhibitory effect on CD8+ T cells. Reversing the expression of TIM-1 in Bregs can facilitate the conversion of Bregs into antitumor B cells and enhance the tumor-elimination capacity of cytotoxic T cells (Fig. 3) [98, 99]. In future studies, focus can be placed on whether B cells, particularly Bregs, play critical roles in key steps of the metastatic cascade. Given that Bregs have been reported to secrete factors such as IL-10 in an HCC mouse model [100], and IL-10 has also been proven to promote EMT [101], further in-depth study is needed to determine whether Bregs facilitate EMT via secreting IL-10 and thereby contribute to the metastatic cascade. Additionally, as detailed earlier, Bregs can suppress the function of CTLs. Whether they assist CTCs in evading immune surveillance during circulation also warrants further investigation. In summary, B cells exert dual roles in HCC metastasis. They can indirectly inhibit HCC metastasis by assisting cytotoxic T lymphocytes (CTLs) and directly eliminate tumor cells by differentiating into plasma cells to prevent the migration of primary tumor cells. Meanwhile, tumor cells promote the formation of Bregs to establish an immunosuppressive microenvironment, laying the microenvironmental foundation for metastasis. T cells T cells, as a core component of the immune microenvironment, play a pivotal role in the TIME. T cells can directly or indirectly eliminate tumor cells to combat metastasis. However, exhaustion and senescence markedly impair their antitumor capacity. T cell exhaustion and senescence are two critical dysfunctional states in patients with HCC. They collectively impede effective antitumor immune responses and sustain an immunosuppressive tumor microenvironment, thereby laying a solid microenvironmental foundation for HCC metastasis [102–104]. As pivotal antitumor effector cells in the TIME, CD8+ T cells exhibit compromised and unstable antitumor activity, accompanied by a high susceptibility to immune exhaustion. In patients with HBV-associated HCC, the exhaustion of CD8+ T cells not only represents a consistent immune protective mechanism that alleviates liver damage but also restricts the effective control of pathogens and tumors [105]. Functional exhaustion of CD8+ T cells is a prerequisite for HCC metastasis. The lack of stable immune surveillance of tumor cells promotes HCC metastasis. Recent studies have shown that CD8+ T cells predominantly accumulate within vessels encapsulating tumor clusters (VETCs), a distinctive vascular subtype that mediates the early noninvasive metastatic cascade of HCC. Notably, these CD8+ T cells predominantly exhibit an exhausted PD-1+ phenotype [106]. Furthermore, CD8+ T cells are susceptible to regulation by immunosuppressive cells such as MDSCs and TAMs, and undergo functional exhaustion in the TIME. For instance, the antitumor activity of CD8+ T cells was affected by indoleamine 2,3-dioxygenase (IDO), arginase 1 (Arg-1), and TGF-β secreted by MDSCs [107]. Moreover, owing to the extremely hypoxic nature of the TME, the expression levels of hypoxia-inducible factor 1/2α (HIF-1/2α) are significantly elevated in HCC and are significantly associated with unfavorable clinical outcomes [108]. The cytotoxicity of CD8⁺ T cells is impaired, and their apoptosis is induced by HIF‑1α‑activated TAMs. Mechanistically, HIF‑1α upregulates the expression of triggering receptor expressed on myeloid cells 1 (TREM1) in TAMs [109]. In addition to regulation by immunosuppressive cells, the function of CD8+ T cells is also modulated by metabolites within the TME. Specifically, CD8⁺ T cells undergo functional exhaustion due to excessive lactic acid in hypoxic microenvironments under the Warburg effect, which further promotes the formation of an immunosuppressive microenvironment [110]. Subsequently, an immune checkpoint analysis of functionally exhausted CD8+ T cells revealed high expression levels of inhibitory receptors, including PD-1, CTLA-4, TIM-3, and LAG-3. The elevated expression of these inhibitory receptors, also known as immune checkpoints, potently inhibits the functions of CD8+ T cells (Fig. 3) [111, 112]. This finding also offers valuable guidance for ICI therapy. By blocking these inhibitory receptors, it becomes possible to restore the antitumor activity of CD8+ T cells. In summary, functional exhaustion of CD8+ T cells not only directly drives the initiation of the metastatic cascade but also indirectly facilitates tumor cells to evade immune surveillance and thereby promote HCC metastasis. As classic helper immune cells, CD4+ T cells play an irreplaceable role in maintaining and augmenting the antitumor activity of CTLs [113]. In comparison with the adjacent tissues of the tumor, the quantities of CD4 effector memory T cells (CD4+ Tem) and CD4+ Tregs are remarkably elevated [114]. The role of CD4+ T cells in HCC metastasis is also dual, although CD4+ T cells within the tumor tissues of HCC display a greater level of activation as compared with the corresponding cells in the blood circulation. Simultaneously, they also manifest a more pronounced exhausted phenotype [115]. For instance, tumor antigens can facilitate the expansion of CD4+ T cells by driving choline acetyltransferase (ChAT), thus promoting the antitumor immune response and restraining HCC metastasis [116]. Specific knockout of ChAT is employed to demonstrate the plasticity of CD4+ T cells. This leads to an increase in the activity of the inhibitory receptor PD-1, which in turn suppresses antitumor immune response and promotes HCC metastasis (Fig. 3) [117]. Notably, Tregs, as one of the most intensively investigated subsets within CD4+ T cells, have been firmly established to be intricately associated with HCC metastasis [118]. CD4+ Tregs can not only directly engage in the metastatic cascade but also indirectly facilitate metastasis by suppressing CTLs or NK cells to establish an immunosuppressive microenvironment. Specifically, a large number of TNFRSF4+ Tregs and Ki67+ Tregs are present in VETC, and the density of Tregs is positively correlated with the proliferation of metastatic HCC cells [106]. Furthermore, CD4+ Treg cells also serve as the core mediators in the formation of immunosuppressive microenvironment to facilitate HCC metastasis. Following tumor formation, Th17 cells are recruited by TGF-β and differentiated into CD4+ Tregs to facilitate HCC metastasis. Exosomes secreted by tumor cells promote the conversion of naive CD4+ T cells (CD4+ Tn) into Tregs. Moreover, the binding of numerous chemokines to their receptors within the TME also contributes to the augmentation of CD4+ Tregs (Fig. 3) [119]. Furthermore, mature CD4+ Tregs can be recruited by TAM to secrete factors such as interleukin 10 (IL-10) to promote the transformation of CD4+ Tn into CD4+ Tregs [54]. Intriguingly, TAN can produce IL-10 to recruit CD4+ Tregs to further inhibit the tumor-elimination function of CTLs [120]. The numerous mechanisms described above contribute to the enrichment of CD4+ Tregs within the TIME. Then, CD4+ Tregs can impair the proliferation and tumor-elimination capacity of NK cells by secreting TGF-β that binds to the TGF-β receptor on NK cells [121]. Beyond engaging in crosstalk with immune cells, CD4+ Tregs are also capable of remodeling stromal cells, which can interact with cancer-associated fibroblasts (CAFs) by secreting TGF-β and IL-10 [122]. This interaction not only promotes the activation of CAFs but also remodels the ECM, thus facilitating the metastasis of HCC (Fig. 3). In summary, as core immune cells in the TIME, CD8+ T cells struggle to exert their antitumor functions owing to crosstalk with multiple immunosuppressive cells, leading to functional exhaustion and direct involvement in the metastatic cascade. In contrast, most CD4+ T cells are polarized into CD4+ Tregs, which primarily shape a metastasis-permissive microenvironment to indirectly facilitate HCC metastasis. These findings also provide insights for subsequent immunotherapy development, for example, by blocking crosstalk between immunosuppressive cells and inhibiting inhibitory receptors on T cells to restore their native immune functions, thereby attenuating HCC metastasis. Novel mechanisms of immune cells in promoting HCC metastatic cascade In the third section, the distinct roles of innate and adaptive immune cells in HCC metastasis were systematically elaborated. Mechanistically, these immune cells facilitate HCC metastasis in two ways: direct involvement in the metastatic cascade and indirect promotion through remodeling a metastasis-permissive microenvironment [106]. The latter effect is generally more prominent, as it involves the coordinated action of multiple immune cell populations. Specifically, immunosuppressive cells, including TAMs, TANs, MDSCs, and Tregs, interactively recruit each other to construct a pervasive immunosuppressive network in the early metastatic stage. This network markedly impairs the antitumor activity of CTLs and NK cells [54, 56, 57, 63, 123–125]. As the core of the immunosuppressive network, tumor cells can recruit the abovementioned immunosuppressive cells or promote the transformation of local immune progenitor cells into immunosuppressive cells by secreting various exosomes, further assisting themselves in immune escape and initiating the subsequent metastatic cascade (Fig. 4). Thus, the formation of the metastasis-permissive microenvironment is a complex process dominated by tumor cells and assisted by various immunosuppressive cells. It acts as an initiating factor throughout the entire HCC metastatic cascade. In addition, the mechanism by which immune cells directly participate in the metastatic cascade have garnered growing attention. Accumulating studies have recently uncovered novel regulatory mechanisms linking immune cells to metastatic cascade, which primarily encompass three processes: facilitating EMT, promoting tumor cell extravasation and colonization, and establishing the premetastatic niche.Fig. 4Novel mechanisms of immune cells in promoting HCC metastatic cascade. The formation of metastasis-permissive microenvironment is a prerequisite for metastasis. TAMs can promote the recruitment of MDSCs and Tregs by secreting exosomes. TANs can also recruit MDSCs and Tregs by secreting NETs. As core cells of the immunosuppressive network, MDSCs and Tregs can significantly inhibit the antitumor effects of CTLs and NK cells. The combined effect of these multiple immunosuppressive cells is key to the formation of metastasis-permissive microenvironment. As a critical step in the metastatic cascade, EMT can be promoted by TAMs through the secretion of TGF-β, IL-10, and CCL7. TGF-β can promote EMT by activating GATA3 to inhibit CAPZA1. Additionally, CDCC110 can enhance this response by binding to the TGFBR on tumor cells. Then, MMP9 secreted by TAMs can also attenuate the IFN/JAK/STAT pathway to promote extravasation and colonization, which can also be enhanced by MMP12. In addition, MMP9 can also activate CK19+ tumor cells via VEGFA to stimulate angiogenesis and metastasis. In the process of establishing premetastatic niche, SPP1 secreted by tumor cells can bind to CD44 on alveolar epithelial cells, thereby facilitating colonization. This interaction can be further enhanced by NETs released by TANs. Then, macrophages can promote the expression of SAA3 in alveolar epithelial cells by releasing IL-1β and NF-κB to accumulate the expression of MMP9 Novel mechanisms of immune cells in promoting HCC metastatic cascade. The formation of metastasis-permissive microenvironment is a prerequisite for metastasis. TAMs can promote the recruitment of MDSCs and Tregs by secreting exosomes. TANs can also recruit MDSCs and Tregs by secreting NETs. As core cells of the immunosuppressive network, MDSCs and Tregs can significantly inhibit the antitumor effects of CTLs and NK cells. The combined effect of these multiple immunosuppressive cells is key to the formation of metastasis-permissive microenvironment. As a critical step in the metastatic cascade, EMT can be promoted by TAMs through the secretion of TGF-β, IL-10, and CCL7. TGF-β can promote EMT by activating GATA3 to inhibit CAPZA1. Additionally, CDCC110 can enhance this response by binding to the TGFBR on tumor cells. Then, MMP9 secreted by TAMs can also attenuate the IFN/JAK/STAT pathway to promote extravasation and colonization, which can also be enhanced by MMP12. In addition, MMP9 can also activate CK19+ tumor cells via VEGFA to stimulate angiogenesis and metastasis. In the process of establishing premetastatic niche, SPP1 secreted by tumor cells can bind to CD44 on alveolar epithelial cells, thereby facilitating colonization. This interaction can be further enhanced by NETs released by TANs. Then, macrophages can promote the expression of SAA3 in alveolar epithelial cells by releasing IL-1β and NF-κB to accumulate the expression of MMP9 Facilitating EMT During the metastatic cascade, EMT is a critically important step, which enables tumor cells to acquire motility and migratory capabilities [43]. It is also the central step by which most immunosuppressive cells promote HCC metastasis. An increasing number of studies have demonstrated that TGF-β serves as a crucial inducer by which immunosuppressive cells promote EMT [126]. For instance, TAMs secrete TGF-β, IL-10, and CCL7 to promote tumor cell stemness and facilitate EMT progression [55, 58, 127]. Furthermore, capping actin protein of muscle Z-line subunit alpha 1 (CAPZA1) plays a vital role in stabilizing actin filaments and maintaining the structure of sarcomeres. Nevertheless, the expression of CAPZA1 is remarkably decreased in HCC. TGF-β secreted by immunosuppressive cells reduces the expression level of CAPZA1 in HCC by downregulating the transcription factor GATA3, which subsequently promotes the metastasis of HCC through EMT. Targeting the TGF-β–GATA3–CAPZA1 signaling pathway is expected to become a new therapeutic target for HCC [128]. Notably, coiled-coil domain containing 110 (CCDC110) plays a significant role in cytoskeletal organization, intracellular transport, and cell signaling transduction. In particular, CCDC110 interacts with TGFBR1 to enhance the stability of TGFBR1 in the cytoplasm. Subsequently, the CCDC110–TGFBR1 axis stimulates EMT by activating the TGF-β–SMAD signaling pathway, thereby enhancing the metastatic capacity of HCC (Fig. 4) [129]. Currently, research on the mechanisms by which immunosuppressive cells promote EMT remains insufficient, and a systematic theory has not been formed. Most studies on EMT still focus on tumor cells, which also provides guidance for subsequent study on the mechanisms of immunosuppressive cells promoting EMT. Although TGF-β plays a crucial role in EMT, a growing number of studies have shown that EMT is an extremely complex process involving multiple key pathways. We have summarized some of the latest studies in Table 1. Dihydrolipoyl transacetylase (DLAT) promotes metastasis by driving metabolic reprogramming of HCC cells. Mechanistically, DLAT enhances the expression of glucose transporter 1 (GLUT1) through H3K18 acetylation, thereby promoting aerobic glycolysis and EMT, and enhancing HCC metastasis [130]. In addition, C5ORF13 interacts with eukaryotic translation initiation factor 6 (eIF6) in HCC cells and promotes EMT and HCC metastasis by regulating eIF6 protein expression. Knockdown of C5ORF13 or eIF6 significantly inhibits lung metastasis of HCC [13]. Notably, the role of RNA regulatory networks in promoting EMT has received attention. The lncRNA/circRNA–miRNA–mRNA regulatory network centered on miRNAs has been confirmed to promote EMT and HCC metastasis [131]. Interestingly, HDAC11 has been reported to be significantly upregulated in HCC and can promote the proliferation of HCC cells. However, HDAC11 can also reduce TGF-β1 transcription, reverse EMT and simultaneously inhibit HCC metastasis. This contradictory phenomenon of promoting proliferation but inhibiting metastasis further illustrates that EMT is an extremely complex biological process [132]. In summary, TGF-β is a typical driver of EMT, yet EMT is regulated by multiple complex mechanisms. Single TGF-β blockade fails to reverse EMT, indicating the necessity of multi-pathway combined intervention and combination therapy. Future studies should focus on how crosstalk between immunosuppressive cells and tumor cells regulates the EMT pathway. Comparing diverse EMT mechanisms can help screen core therapeutic targets, thereby achieving efficient inhibition of HCC metastasis.Table 1Novel mechanisms promoting EMT in HCC metastasisCell typeInitiating factorMechanismReferencesTumor cellDLATUpregulating GLUT1 via H3K18 acetylation[130]C5ORF13Interacting with eIF6[13]MYBBP1APromoting the NOTCH1 signaling pathway via downregulation of IGFBP4[133]miR-30d-5pPromoting ERK and GSK3β signals signaling pathway via downregulation of CASP1[134]miRNAVia lncRNA/circRNA–miRNA–mRNA network[131]GINS1Promoting ZEB1 via β-catenin signaling[135]β-cateninDownregulating NLRP3[136]NSUN5Enriching SMAD3 by recruiting WDR5[137]–Promoting the PI3K/Akt signaling pathway[138]Promoter methylationPromoting the PI3K/ATK signaling pathway via downregulation of PDE7B[139]TAMTREM1Secreting CCL7[58]miR-98Secreting IL-10[127] Table 1Novel mechanisms promoting EMT in HCC metastasisCell typeInitiating factorMechanismReferencesTumor cellDLATUpregulating GLUT1 via H3K18 acetylation[130]C5ORF13Interacting with eIF6[13]MYBBP1APromoting the NOTCH1 signaling pathway via downregulation of IGFBP4[133]miR-30d-5pPromoting ERK and GSK3β signals signaling pathway via downregulation of CASP1[134]miRNAVia lncRNA/circRNA–miRNA–mRNA network[131]GINS1Promoting ZEB1 via β-catenin signaling[135]β-cateninDownregulating NLRP3[136]NSUN5Enriching SMAD3 by recruiting WDR5[137]–Promoting the PI3K/Akt signaling pathway[138]Promoter methylationPromoting the PI3K/ATK signaling pathway via downregulation of PDE7B[139]TAMTREM1Secreting CCL7[58]miR-98Secreting IL-10[127] Novel mechanisms promoting EMT in HCC metastasis Promoting tumor cell extravasation and colonization During the metastatic cascade, extravasation and colonization represent the terminal metastatic stages, accompanied by substantial ECM remodeling. Remodeled ECM further facilitates tumor cell proliferation, invasion, and metastasis to promote HCC progression. Notably, MMPs secreted by immunosuppressive cells play a significant role in remodeling the ECM and promoting tumor progression and metastasis [140]. For instance, SPP1+ TAMs activate the VEGFA signaling pathway by secreting MMP9 to stimulate CK19+ HCC tumor stem cells, thus facilitating angiogenesis and metastasis [141]. Moreover, MMP9 secreted by TAMs within the TIME of HBV-associated HCC exerts a crucial role in promoting tumor progression, invasion, angiogenesis, and metastasis by inhibiting the IFN–JAK–STAT signaling pathway [142]. Additionally, another study demonstrated that MMP9 impairs the antitumor activity of CTLs, thereby promoting tumor cell immune evasion during extravasation and colonization. Thus, blockade of MMP9 can reshape the TIME and enhance the sensitivity to anti-PD-1 therapy [143]. Besides MMP9, MMP12 expression is positively correlated with the infiltration level of immunosuppressive cells in the TIME. MMP12 overexpression is closely linked to vascular invasion and poor clinical prognosis [144]. Apart from that, immunosuppressive cells are capable of secreting MMPs, and CAFs among stromal cells can also interact with tumor cells to generate MMPs, thereby facilitating ECM remodeling (Fig. 4) [145]. Therefore, blocking the secretion of MMPs by immunosuppressive cells is crucial for reversing ECM remodeling, which can suppress the extravasation and colonization of tumor cells and inhibit HCC metastasis. Establishing the premetastatic niche Prior to the establishment of metastatic lesions, tumor cells typically secrete a variety of exosomes to reshape the local TIME within the metastatic sites, thereby facilitating the colonization and growth of tumor cells. This phenomenon is commonly termed as the formation of the premetastatic niche. The lung is the most common distant organ for HCC metastasis, and its abundant capillary network facilitates tumor cell colonization. The process of HCC lung metastasis is often accompanied by the establishment of a premetastatic niche [146]. Therefore, this review takes lung metastasis as an example to elaborate on the mechanisms by which immunosuppressive cells establish the premetastatic niche. In a recent study focusing on the lung metastasis of HCC, tumor cells secrete SPP1, which binds to the CD44 receptor on alveolar epithelial cells. This binding action recruits a greater number of neutrophils and drives their transformation into TANs, which then secrete an increased amount of NETs. NETs further capture tumor cells and facilitate their colonization and metastasis. Reversing local TIME domestication by SPP1 through targeting the CXCL1–CXCR2 axis and NETs can effectively suppress lung metastasis of HCC [147]. Simultaneously, within the premetastatic tissues of the murine model of HCC lung metastasis, the accumulation of myeloid cells has been observed. This accumulation establishes an environmental basis for subsequent lung metastasis. Mechanistically, alveolar macrophages, stimulated by IL-1β and NF-κB, significantly enhance the expression of serum amyloid A3 (SAA3) in alveolar epithelial cells and increase the expression of MMP9 in an autocrine manner, thereby facilitating the extravasation and colonization of tumor cells (Fig. 4) [148]. Although the above mechanisms have been preliminarily verified in lung metastasis, HCC can also metastasize to the bone, lymph nodes, and adrenal glands [11–14]. Therefore, these mechanisms need to be further validated in other metastatic sites of HCC. Notably, as another common metastatic organ of HCC, the bone also forms a premetastatic niche-like microenvironment to facilitate CTC colonization. Immune cells such as osteoclasts are also widely involved in this process, but detailed elaboration on the above mechanisms is currently lacking [149]. Interestingly, CTCs enter a special dormant state to evade immune surveillance after entering the bone marrow cavity, and whether immunosuppressive cells are involved in this process requires further investigation [150]. Evidently, the establishment of the premetastatic niche and the colonization of tumor cells are mutually complementary processes. Tumor cells secrete exosomes to recruit immunosuppressive cells to the site of colonization. Subsequently, these immunosuppressive cells undergo functional alterations, which contribute to the shaping of an immunosuppressive premetastatic niche. Conversely, the niche fosters the colonization of tumor cells, thereby establishing a positive feedback loop of mutual promotion. Novel mechanisms of tumor immunoresistance during metastasis During the metastatic cascade, tumor cells also undergo adaptive changes to evade immune surveillance. Specifically, they can develop immune resistance by editing antigens, undergoing metabolic reprogramming, recruiting more suppressive immune cells, or upregulating other immune checkpoints [151–153]. The successful extravasation and colonization of CTCs are critical determinants of HCC metastasis. Mechanistically, CTCs secrete high levels of interleukin 8 (IL-8) to activate downstream MMP9, which facilitates CTC-mediated extravasation and distant colonization [141, 154]. Elevated IL-8 expression is strongly correlated with adverse clinical outcomes and contributes to HCC metastatic progression. In addition, abundant IL1α+ monocytes accumulate in the HCC microenvironment, which can promote tumor cells to produce IL-8 and thus assist distant metastasis [152]. Furthermore, studies have reported that CTCs also edit their own antigens to achieve immune escape during metastasis. The specific mechanism is that CTCs downregulate SGK1 in circulation to evade immune surveillance. Loss of SGK1 enables CTCs to resist CTL-induced cytotoxicity, thereby promoting metastatic colonization [153]. Meanwhile, tumor cells also recruit PMN-MDSCs by upregulating ETV5 and increase their own expression of PD-L1 and S100A9 to assist in immune escape during metastasis [76]. In addition, the expression level of AID in tumor cells increases during HCC metastasis. As a transcription factor of JAG1, AID plays an important role in HCC metastasis through the NOTCH–c-FOS axis (Fig. 5) [155]. With the advancement of single-cell omics, significantly elevated HMGB2 expression has been detected in metastatic liver cancer, and HMGB2 expression is positively correlated with the immunosuppressive microenvironment. Specifically, exhausted CTLs significantly upregulate HMGB2 [156]. However, owing to the limitation of transcriptomics, this conclusion has certain limitations. It is necessary to further explore whether the expression level of HMGB2 gradually increases during metastasis and to investigate the specific mechanism by which it exhausts CTLs.Fig. 5Novel mechanisms of tumor immunoresistance during metastasis. Immunoresistance during metastasis mainly involves three aspects: antigen editing, metabolic reprogramming, and upregulating immune checkpoints. In terms of antigen editing: CTC can secrete IL-8 to stimulate the production of MMP9, thereby promoting extravasation and metastasis. This process can be enhanced by IL-1α⁺ monocytes. Meanwhile, tumor cells can downregulate SGK1 expression to achieve immune evasion and reshape the metastasis-permissive microenvironment. ETV5 can also upregulate S100A9 and PD-L1 in CTCs to promote extravasation and immune evasion. Additionally, tumor cells can promote the expression of AID via JAG1 to enhance the NOTCH pathway and facilitate metastasis. In terms of metabolic reprogramming, lactate and lipids in the microenvironment can upregulate the CD36 immune checkpoint in Tregs, TAMs, CTLs, and NK cells to reshape the metastasis-permissive microenvironment. Hypoxia can also increase miR-1290 in exosomes secreted by tumor cells, which upregulates PD-L1 expression to promote metastasis. In terms of upregulating immune checkpoints, tumor cells can upregulate the B7-H3 immune checkpoint to promote angiogenesis and EMT, thereby facilitating metastasis Novel mechanisms of tumor immunoresistance during metastasis. Immunoresistance during metastasis mainly involves three aspects: antigen editing, metabolic reprogramming, and upregulating immune checkpoints. In terms of antigen editing: CTC can secrete IL-8 to stimulate the production of MMP9, thereby promoting extravasation and metastasis. This process can be enhanced by IL-1α⁺ monocytes. Meanwhile, tumor cells can downregulate SGK1 expression to achieve immune evasion and reshape the metastasis-permissive microenvironment. ETV5 can also upregulate S100A9 and PD-L1 in CTCs to promote extravasation and immune evasion. Additionally, tumor cells can promote the expression of AID via JAG1 to enhance the NOTCH pathway and facilitate metastasis. In terms of metabolic reprogramming, lactate and lipids in the microenvironment can upregulate the CD36 immune checkpoint in Tregs, TAMs, CTLs, and NK cells to reshape the metastasis-permissive microenvironment. Hypoxia can also increase miR-1290 in exosomes secreted by tumor cells, which upregulates PD-L1 expression to promote metastasis. In terms of upregulating immune checkpoints, tumor cells can upregulate the B7-H3 immune checkpoint to promote angiogenesis and EMT, thereby facilitating metastasis Interestingly, tumor cells can also alter local metabolism to induce immune cells to upregulate inhibitory immune checkpoints for immune escape, thereby promoting metastasis. In the metabolic microenvironment enriched in lipids and lactate, the expression of CD36 is significantly upregulated in Tregs and metastasis-associated TAMs, which synergistically promote tumor cells to achieve immune escape. Meanwhile, CD36 is also upregulated in CTLs and NK cells, thereby weakening their antitumor capacity, creating metastasis-permissive microenvironment [112]. In addition to metabolic reprogramming, hypoxia is another important factor contributing to HCC metastasis. In the hypoxic microenvironment, the expression level of miR-1290 in exosomes secreted by tumor cells is significantly increased. miR-1290 can not only promote tumor cells to upregulate PD-L1 to evade immune surveillance but also induce TAM polarization and CTL apoptosis. While creating a metastasis-permissive microenvironment, it also promotes EMT to further facilitate HCC metastasis (Fig. 5) [157]. In addition to upregulating PD-L1 during metastasis, tumor cells also upregulate B7-H3 (CD276), another important immunosuppressive checkpoint [151]. The expression of B7-H3 is associated with aggressive clinicopathological features such as vascular invasion and metastasis [158]. Upregulation of B7-H3 not only enhances the EMT capacity of tumor cells but also directly inhibits the proliferation and local infiltration of CTLs, dynamically reshaping the TIME during metastasis. B7-H3 is a potent immunosuppressive pathway in metastatic HCC and plays a pivotal role in HCC metastasis (Fig. 5) [159]. In summary, tumor cells, particularly CTCs, dynamically remodel the TIME throughout metastatic progression. Accordingly, targeting these dysregulated molecular mechanisms may provide promising therapeutic candidates to block early metastatic lesion formation. Targeting the TIME against HCC metastasis: from mechanisms to clinical practice Deficiencies of clinical trials of immunotherapies for metastatic HCC Currently, clinical trials of immunotherapy for metastatic HCC mainly focus on ICI and chimeric antigen receptor T cell (CAR-T) therapies. We have collated the major clinical trials in Table 2. However, the results of most clinical trials for metastatic HCC are disappointing, and most of these trials have not yet yielded conclusive results. The underlying reason may be attributed to the extremely strong internal heterogeneity of metastatic HCC. The immunosuppressive microenvironment has always been an important factor in reducing the efficacy of immunotherapy. Unfortunately, the majority of clinical trials have not yet fully recognized the influence of the immunosuppressive microenvironment on immunotherapy. Instead, they simply combine existing therapies to assess whether patients can derive benefits. Consequently, in future clinical trials, emphasis should not only be placed on the development of novel drugs but also on reversing the adverse effects imposed by the immunosuppressive microenvironment. In the era of precision medicine, clinical trials ought to place greater emphasis on individual variations. Only in this way can the efficacy of immunotherapy be enhanced more effectively.Table 2Clinical trials of immunotherapies for advanced and metastatic HCCNCT no.StatusPhaseTreatmentCombination agentInterventionORR/PFS/OSReferencesNCT05063565Active, not recruitingPhase 2TheraSphere Y-90Durvalumab and tremelimumabTheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure; durvalumab (Imfinzi): 1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor; tremelimumab: 300 mg, single administrationOngoing–NCT01760616TerminatedPhase 4Huaier GranuleImmunotherapyHuaier Granule is a Chinese medicine, specifications: 20 g/bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd.Ongoing–NCT06876753Recruiting–TACEPD-(L)1 inhibitors–Ongoing–NCT05665348RecruitingPhase 2/3IpilimumabAtezolizumab and bevacizumabIpilimumab: administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm; atezolizumab and bevacizumab: one of the standard treatment options for HCC managementOngoing–NCT06144385RecruitingPhase 1CAR-GPC3 T cells–CAR-GPC3 T cells: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204. During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injectionOngoing–NCT05809869RecruitingPhase 2Yttrium-90 radioembolisationDurvalumab and tremelimumabYttrium-90 radioembolization on week 2 only; durvalumab 1500 mg intravenous infusion on week 1, 5, 9, 13, 17, 21, and 25 for a total of seven cycles; tremelimumab 300 mg intravenous infusion on week 1 onlyOngoing–NCT06261125RecruitingPhase 2Stereotactic body radiotherapy (SBRT)Adebrelimab and lenvatinibPatients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 33–48 Gy in six fractions over 2 weeks; all patients will receive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT; all patients will receive lenvatinib (12 mg/day for body weight ≥ 60 kg or 8 mg/day for body weight < 60 kg) orally once daily after the completion of SBRTOngoing–NCT04313868CompletedPhase 1GEN2–GEN2 is an investigational drug combining cytotoxic therapy and immunotherapyNot reported–NCT03575806CompletedPhase 2TACEAutologous Tcm immunotherapyTranscatheter arterial chemoembolization (TACE); autologous Tcm immunotherapy: to collect patient’s own immune cells and then given back to the patient after amplified in vitroThe median follow-up time was 20.5 months (95% CI: 17.05–22.55 months). The median RFS time was 9.5 months in the control group; the cutoff date was not reached in the Tcm group (when the follow-up duration was 12 months, p = 0.049, HR = 0.40; 95% CI: 0.16–0.99). Compared with the control group, 1- and 2-year RFS rates were higher in the Tcm group (72.0% versus 46.4% and 58.18% versus 39.14%, respectively)[132]NCT05003895RecruitingPhase 1CAR-TCyclophosphamide and fludarabineCAR-T cell: single infusion on day 0; cyclophosphamide: daily × three doses on days −3, −2, and −1 at 300 mg/m2 IV infusion (200 mg/m2 at dose level −1); fludarabine: daily × two doses on days −2 and −1 at 30 mg/m2 IV infusion administered following cyclophosphamideOngoing–NCT02882659UnknownPhase 1Dendritic killer cell (DKC)–DKC is a hybrid cell type capable of dual functionality, i.e., cytotoxicity and antigen presentation, similar to NK cells and DCs, respectivelyOngoing–NCT07174570Not yet recruitingPhase 2CelecoxibDurvalumab and tremelimumabCelecoxib: receive by mouth (PO); durvalumab and tremelimumab: receive IVOngoing–NCT03937830Active, not recruitingPhase 2TACEDurvalumab, bevacizumab and tremelimumabTACE with doxorubicin-eluting beads (only in patients with HCC BCLC stage B) on cycle 2. More TACE can be performed if clinically necessary; durvalumab: 1150 mg flat dose every 21 days, starting on day 1 of cycle 1; bevacizumab:7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2; tremelimumab: 300, 150, or 75 mg once on day 1 of cycle 1Ongoing–NCT06089382Not yet recruitingPhase 3TACESintilimab and lenvatinibOne cycle of TACE postoperatively; sintilimab:IV infusion of sintilimab (200 mg intravenously every 3 weeks for a total of 18 cycles or tumor recurrence); lenvatinib: 8 mg orally once a day for 1 yearOngoing–NCT06893887RecruitingNot applicableFOLFOX4AdebrelimabFOLFOX4 was administered by oxaliplatin 85 mg/m2 d1 + leucovorin 200 mg/m2 d1-2 + fluorouracil 400 mg/m2 2 h → 600 mg/m2 24 h d1-2 q2w, with a total of four cycles; adebrelimab 1200 mg, intravenous infusion, every 3 weeksOngoing–NCT00027534CompletedPhase 1TRICOM-CEA(6D)–Dendritic cells loaded with TRICOM-CEA(6D)Not reported–NCT01522820CompletedPhase 1DEC-205/NY-ESO-1 fusion protein CDX-1401–DEC-205/NY-ESO-1 fusion protein CDX-1401: given intranodallyImmediate (days 1–14 postvaccination) or delayed (days 15–28 postvaccination) administration of rapamycin led to a significant increase in the generation of vaccine-induced NY-ESO-1-specific T cells exhibiting central memory phenotypes (CD45RO+ CD45RA− CCR7+). Moreover, delayed administration resulted in a greater than threefold (p = 0.025) and eightfold (p = 0.005) increase in the frequency of NY-ESO-1-specific CD4+ T and CD8+ T cells, respectively, at the time of long-term follow-up, compared with its immediate usage[133]NCT04912765RecruitingPhase 2Neoantigen dendritic cell (NA DC) vaccineNivolumabNeoantigen dendritic cell vaccineTen doses of the vaccine will be administered via intradermal injection concurrently with adjuvant nivolumab; nivolumab: 9 doses of 240 mg IV nivolumab as a 30-min infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of ten doses of NA DC vaccine, 480 mg IV nivolumab will be administered as a 30-min infusion for a maximum of nine dosesOngoing–NCT07075120Not yet recruitingPhase 1SBRTIpilimumab and nivolumabImmunotherapy combination (ipilimumab and nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response; SBRT: high-dose radiation therapy delivered in three to five fractions for local control of tumors in combination with immunotherapyOngoing–Data sources: https://clinicaltrials.gov/. Table 2Clinical trials of immunotherapies for advanced and metastatic HCCNCT no.StatusPhaseTreatmentCombination agentInterventionORR/PFS/OSReferencesNCT05063565Active, not recruitingPhase 2TheraSphere Y-90Durvalumab and tremelimumabTheraSphere Y-90 glass microsphere therapy administered through the hepatic artery at index procedure; durvalumab (Imfinzi): 1500 mg, every 4 weeks that continues for a maximum duration of 18 months or until confirmed progression (by site assessment), unacceptable toxicity, study withdrawal, or study early termination by the sponsor; tremelimumab: 300 mg, single administrationOngoing–NCT01760616TerminatedPhase 4Huaier GranuleImmunotherapyHuaier Granule is a Chinese medicine, specifications: 20 g/bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd.Ongoing–NCT06876753Recruiting–TACEPD-(L)1 inhibitors–Ongoing–NCT05665348RecruitingPhase 2/3IpilimumabAtezolizumab and bevacizumabIpilimumab: administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm; atezolizumab and bevacizumab: one of the standard treatment options for HCC managementOngoing–NCT06144385RecruitingPhase 1CAR-GPC3 T cells–CAR-GPC3 T cells: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204. During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injectionOngoing–NCT05809869RecruitingPhase 2Yttrium-90 radioembolisationDurvalumab and tremelimumabYttrium-90 radioembolization on week 2 only; durvalumab 1500 mg intravenous infusion on week 1, 5, 9, 13, 17, 21, and 25 for a total of seven cycles; tremelimumab 300 mg intravenous infusion on week 1 onlyOngoing–NCT06261125RecruitingPhase 2Stereotactic body radiotherapy (SBRT)Adebrelimab and lenvatinibPatients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 33–48 Gy in six fractions over 2 weeks; all patients will receive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT; all patients will receive lenvatinib (12 mg/day for body weight ≥ 60 kg or 8 mg/day for body weight < 60 kg) orally once daily after the completion of SBRTOngoing–NCT04313868CompletedPhase 1GEN2–GEN2 is an investigational drug combining cytotoxic therapy and immunotherapyNot reported–NCT03575806CompletedPhase 2TACEAutologous Tcm immunotherapyTranscatheter arterial chemoembolization (TACE); autologous Tcm immunotherapy: to collect patient’s own immune cells and then given back to the patient after amplified in vitroThe median follow-up time was 20.5 months (95% CI: 17.05–22.55 months). The median RFS time was 9.5 months in the control group; the cutoff date was not reached in the Tcm group (when the follow-up duration was 12 months, p = 0.049, HR = 0.40; 95% CI: 0.16–0.99). Compared with the control group, 1- and 2-year RFS rates were higher in the Tcm group (72.0% versus 46.4% and 58.18% versus 39.14%, respectively)[132]NCT05003895RecruitingPhase 1CAR-TCyclophosphamide and fludarabineCAR-T cell: single infusion on day 0; cyclophosphamide: daily × three doses on days −3, −2, and −1 at 300 mg/m2 IV infusion (200 mg/m2 at dose level −1); fludarabine: daily × two doses on days −2 and −1 at 30 mg/m2 IV infusion administered following cyclophosphamideOngoing–NCT02882659UnknownPhase 1Dendritic killer cell (DKC)–DKC is a hybrid cell type capable of dual functionality, i.e., cytotoxicity and antigen presentation, similar to NK cells and DCs, respectivelyOngoing–NCT07174570Not yet recruitingPhase 2CelecoxibDurvalumab and tremelimumabCelecoxib: receive by mouth (PO); durvalumab and tremelimumab: receive IVOngoing–NCT03937830Active, not recruitingPhase 2TACEDurvalumab, bevacizumab and tremelimumabTACE with doxorubicin-eluting beads (only in patients with HCC BCLC stage B) on cycle 2. More TACE can be performed if clinically necessary; durvalumab: 1150 mg flat dose every 21 days, starting on day 1 of cycle 1; bevacizumab:7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2; tremelimumab: 300, 150, or 75 mg once on day 1 of cycle 1Ongoing–NCT06089382Not yet recruitingPhase 3TACESintilimab and lenvatinibOne cycle of TACE postoperatively; sintilimab:IV infusion of sintilimab (200 mg intravenously every 3 weeks for a total of 18 cycles or tumor recurrence); lenvatinib: 8 mg orally once a day for 1 yearOngoing–NCT06893887RecruitingNot applicableFOLFOX4AdebrelimabFOLFOX4 was administered by oxaliplatin 85 mg/m2 d1 + leucovorin 200 mg/m2 d1-2 + fluorouracil 400 mg/m2 2 h → 600 mg/m2 24 h d1-2 q2w, with a total of four cycles; adebrelimab 1200 mg, intravenous infusion, every 3 weeksOngoing–NCT00027534CompletedPhase 1TRICOM-CEA(6D)–Dendritic cells loaded with TRICOM-CEA(6D)Not reported–NCT01522820CompletedPhase 1DEC-205/NY-ESO-1 fusion protein CDX-1401–DEC-205/NY-ESO-1 fusion protein CDX-1401: given intranodallyImmediate (days 1–14 postvaccination) or delayed (days 15–28 postvaccination) administration of rapamycin led to a significant increase in the generation of vaccine-induced NY-ESO-1-specific T cells exhibiting central memory phenotypes (CD45RO+ CD45RA− CCR7+). Moreover, delayed administration resulted in a greater than threefold (p = 0.025) and eightfold (p = 0.005) increase in the frequency of NY-ESO-1-specific CD4+ T and CD8+ T cells, respectively, at the time of long-term follow-up, compared with its immediate usage[133]NCT04912765RecruitingPhase 2Neoantigen dendritic cell (NA DC) vaccineNivolumabNeoantigen dendritic cell vaccineTen doses of the vaccine will be administered via intradermal injection concurrently with adjuvant nivolumab; nivolumab: 9 doses of 240 mg IV nivolumab as a 30-min infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of ten doses of NA DC vaccine, 480 mg IV nivolumab will be administered as a 30-min infusion for a maximum of nine dosesOngoing–NCT07075120Not yet recruitingPhase 1SBRTIpilimumab and nivolumabImmunotherapy combination (ipilimumab and nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response; SBRT: high-dose radiation therapy delivered in three to five fractions for local control of tumors in combination with immunotherapyOngoing–Data sources: https://clinicaltrials.gov/. Clinical trials of immunotherapies for advanced and metastatic HCC TACE with doxorubicin-eluting beads (only in patients with HCC BCLC stage B) on cycle 2. More TACE can be performed if clinically necessary; durvalumab: 1150 mg flat dose every 21 days, starting on day 1 of cycle 1; bevacizumab: 7.5 mg/kg dose every 21 days, starting on day 1 of cycle 2; tremelimumab: 300, 150, or 75 mg once on day 1 of cycle 1 One cycle of TACE postoperatively; sintilimab: IV infusion of sintilimab (200 mg intravenously every 3 weeks for a total of 18 cycles or tumor recurrence); lenvatinib: 8 mg orally once a day for 1 year Neoantigen dendritic cell vaccine Ten doses of the vaccine will be administered via intradermal injection concurrently with adjuvant nivolumab; nivolumab: 9 doses of 240 mg IV nivolumab as a 30-min infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of ten doses of NA DC vaccine, 480 mg IV nivolumab will be administered as a 30-min infusion for a maximum of nine doses Data sources: https://clinicaltrials.gov/. Efficacy and challenges of current immunotherapy in metastatic HCC ICIs Immune checkpoints are surface molecules predominantly expressed on immune cells, especially T lymphocytes, which modulate immune response intensity and duration to limit excessive immune activation and protect normal tissues [160]. Mechanistically, PD-1 is expressed on T cells, and its interaction with PD-L1 on normal cells delivers inhibitory signals to restrict T cell cytotoxicity and maintain immune homeostasis. Notably, tumor cells exploit this physiological mechanism by upregulating PD-L1 expression to evade surveillance by CTLs and NK cells, resulting in the inactivation and exhaustion of antitumor effector cells and ultimately facilitating tumor immune evasion. The latest research findings indicate that the higher the expression level of PD-L1 on the surface of HCC cells, the stronger their capacity for vascular invasion and metastasis [161]. Therefore, to combat HCC metastasis and prolong the survival time of patients with advanced HCC, it is essential to interrupt the negative effects induced by immune checkpoints. Currently, the mainstream immunotherapy for HCC is ICIs in clinical practice. Among them, the PD-1–PD-L1 pathway serves as the most crucial therapeutic target. Specifically, this therapy eliminates tumors by blocking the PD-1 receptor on the surface of T cells and the PD-L1 ligand on the surface of tumor cells [162]. On the basis of this, the treatment of advanced HCC has ushered in the era of “immunotherapy combination” [163]. The “T + A” regimen, combining the PD-L1 inhibitor atezolizumab and the anti-angiogenic agent bevacizumab, has become the first-line standard therapy for patients with advanced metastatic HCC [164]. Moreover, numerous studies have demonstrated that the CTLA-4 pathway is also of vital significance in immune surveillance. CTLA-4 is predominantly expressed on the surface of T cells. It primarily exerts its function during the initiation phase of the immune response. By binding to CD80/CD86, it suppresses the early activation of T cells [165]. In the treatment of patients with advanced metastatic HCC, CTLA-4 inhibitors are generally not employed as monotherapy. Instead, they are combined with PD-1/PD-L1 inhibitors to exert a synergistic therapeutic effect and more potently activate the immune system. At present, the combination of nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) has emerged as a second-line treatment regimen (Fig. 6) [166].Fig. 6Current immunotherapies against HCC metastasis. Currently, the primary therapies for patients with metastatic HCC include ICIs, ACT, targeting immunosuppressive cells, tumor vaccines, and oncolytic viruses. The combination of atezolizumab and bevacizumab, as first-line therapies, has been widely used in clinical therapy. In the future, monoclonal antibodies targeting LAG-3, TIM-3, and TIGIT will gradually progress to clinical trials to overcome immunotherapy resistance. Furthermore, anti-MMP14 and anti-CD44E CAR-T cells effectively eliminate CTCs and suppress HCC metastasis, while alleviating the scarcity of tumor-specific antigens. GPC3-targeted CAR-T cells exhibit promising antitumor activity in clinical practice. However, TREM2+ TAMs and elevated SKIV2L restrict the efficacy of CAR-T therapy. Notably, tumor cells can recruit TAMs through the CSF-1–CSF1R and CD74–SIRPα axes and MDSCs through the IL-8–CXCR2 axis to reshape TIME. The efficacy of CSF1R inhibitors and SIRPα inhibitors has been preliminarily verified. Moreover, AZD5069, a CXCR2 antagonist, has entered relevant clinical trials. Finally, tumor vaccines and oncolytic viruses exhibit substantial potential in future immunotherapy. Dendritic cell vaccines can activate CTLs, thereby eliminating tumor cells. JX-594 is the most extensively researched oncolytic virus. While it has demonstrated certain therapeutic effects, its safety requires further validation Current immunotherapies against HCC metastasis. Currently, the primary therapies for patients with metastatic HCC include ICIs, ACT, targeting immunosuppressive cells, tumor vaccines, and oncolytic viruses. The combination of atezolizumab and bevacizumab, as first-line therapies, has been widely used in clinical therapy. In the future, monoclonal antibodies targeting LAG-3, TIM-3, and TIGIT will gradually progress to clinical trials to overcome immunotherapy resistance. Furthermore, anti-MMP14 and anti-CD44E CAR-T cells effectively eliminate CTCs and suppress HCC metastasis, while alleviating the scarcity of tumor-specific antigens. GPC3-targeted CAR-T cells exhibit promising antitumor activity in clinical practice. However, TREM2+ TAMs and elevated SKIV2L restrict the efficacy of CAR-T therapy. Notably, tumor cells can recruit TAMs through the CSF-1–CSF1R and CD74–SIRPα axes and MDSCs through the IL-8–CXCR2 axis to reshape TIME. The efficacy of CSF1R inhibitors and SIRPα inhibitors has been preliminarily verified. Moreover, AZD5069, a CXCR2 antagonist, has entered relevant clinical trials. Finally, tumor vaccines and oncolytic viruses exhibit substantial potential in future immunotherapy. Dendritic cell vaccines can activate CTLs, thereby eliminating tumor cells. JX-594 is the most extensively researched oncolytic virus. While it has demonstrated certain therapeutic effects, its safety requires further validation Although combined immunotherapy can confer benefits to some patients with advanced metastatic HCC, the issue of immune resistance persists in the majority of patients. The underlying reasons are as follows: Firstly, immune cells may exhibit multiple immune checkpoints. Given the individual heterogeneity among patients, the dominant immune checkpoints on immune cells can vary from person to person. Thus, simply or fixedly blocking one or two of these checkpoints may not yield the anticipated therapeutic outcomes. Secondly, tumor cells are capable of continuously adapting to changes in the microenvironment and altering the immune checkpoints they express. This phenomenon accounts for the situation where some patients initially respond well to treatment but subsequently develop resistance. Thirdly, there are substantial alterations in the proportion of immune cells within the TIME compared with normal tissues. Immune cells with tumor-elimination functions are persistently damaged by tumor cells, leading to a marked decline in their quantities. In the absence of adequately activated immune cells, the efficacy of ICIs is rather limited. Fourthly, while the microenvironments of metastatic lesion and primary tumors in patients with metastatic HCC share a common origin, there are inevitably differences between them. These disparities in the TIME determine the varying sensitivities to the same ICIs. Based on the above four points, it is urgent to conduct individualized research on patients with advanced metastatic HCC in clinical practice and formulate individualized therapies for different patients on the basis of the differences of TIME to improve the therapeutic effect and survival time of patients [167]. Fortunately, the identification of emerging immune checkpoints has illuminated the future trajectory of ICIs. The inhibitors of emerging immune checkpoints represented by LAG-3, TIM-3, and TIGIT have entered the corresponding clinical trials and achieved certain therapeutic effects. Additionally, the combination of emerging checkpoint inhibitors and PD-1/PD-L1 inhibitors is poised to revolutionize the treatment landscape for patients with advanced metastatic HCC in the future [168–170]. Adoptive cellular therapy (ACT) ACT represents a crucial branch within the realm of tumor immunotherapy. This approach entails the extraction of immune cells from a patient’s body. Subsequently, these cells are genetically engineered, amplified, and activated in vitro, enabling them to regain the capacity to eliminate tumors. Finally, the modified cells are re-infused back into the patient, thereby facilitating a more efficient eliminating of tumor cells [171]. Currently, well-established therapies include TIL therapy and CAR-T therapy. TIL therapy necessitates the acquisition of lymphocytes (predominantly CD8+ T cells) that have been exhausted by tumor cells from within the patient’s body. Subsequently, these cells are activated in vitro using interleukin-2 (IL-2). After depleting local immunosuppressive cells with chemotherapeutic drugs, the activated cells are re-infused back into the patient’s body. The most recent studies have shown that the degree of CD8+ TIL infiltration serves as a predictive biomarker for the efficacy of TIL therapy [172]. For patients with HCC with advanced metastases, TIL therapy demonstrates certain therapeutic efficacy during the initial treatment phase. However, it cannot be regarded as a first-line therapy. There are several underlying reasons. Firstly, the majority of metastatic patients have usually missed the window of opportunity for surgical intervention. This significantly heightens the difficulty of locally obtaining TILs. Secondly, although the local immunosuppressive microenvironment in metastatic lesions can be temporarily eradicated, tumor cells can reshape an immunosuppressive microenvironment locally, leading to the exhaustion of TILs, thus resulting in unstable therapeutic outcomes of this therapy. Finally, the manufacturing process of TILs for this therapy is intricate, costly, and time-consuming. The extended time required for preparation may potentially cause treatment delays. CAR-T therapy exhibits distinct advantages over TIL therapy, achieving precise tumor elimination and exerting favorable targeting specificity for metastatic lesions [173]. Current studies have demonstrated that anti-MMP14 CAR-T cells can efficiently eliminate CTCs and markedly inhibit metastatic progression in liver cancer models [174]. Furthermore, anti-CD44E CAR-T therapy partially overcomes the key limitation of scarce tumor-specific antigens available for CAR-T cell recognition [175]. Although CAR-T therapy demonstrates certain advantages and achieved partial therapeutic effects in tumor ablation, it is confronted with numerous challenges [176]. The immunosuppressive microenvironment constitutes a primary factor that impairs the therapeutic efficacy of CAR-T therapy [177]. For instance, CAR-T therapies targeting glypican-3 (GPC3), a classic biomarker of HCC, have been developed for clinical application and shown considerable therapeutic efficacy [178]. Nevertheless, their clinical efficacy is often compromised by treatment resistance driven by TREM2+ TAMs in the TIME [179]. Moreover, RNA helicase SKIV2L impairs the therapeutic efficacy of CAR-T therapy by modulating arginine metabolism to reshape the immunosuppressive microenvironment and compromise the function of CTLs (Fig. 6) [180]. Therefore, reversing the immunosuppressive microenvironment is a critical strategy for enhancing the efficacy of CAR-T therapy. Currently, studies have reported the design of CAR-T therapy targeting CD19+ TAM, which not only ameliorates the immunosuppressive microenvironment but also enhances the efficacy of ICI therapy, ultimately inhibiting the growth and metastasis of HCC [181]. Moreover, CAR-T therapy still faces several practical obstacles, including excessive extracellular matrix deposition, tumor fibrosis, and the requirement for patient-specific tumor antigen design, all of which warrant further resolution in future investigations [182]. Overall, ACT has brought new hope to patients with HCC with advanced metastasis. Nevertheless, the majority of these therapies remain in the clinical trial phase, and no standardized treatment protocols have been established yet. In the future, it is essential to focus on the following research directions. Primarily, continuous efforts should be made to expand cell-engineering technologies. This aims to make CAR-T cells more resistant to the immunosuppressive microenvironment within tumors. By enhancing their infiltration ability into solid tumors, the obstacles posed by solid tumors can be effectively overcome. Furthermore, greater attention should be paid to the combination with ICI therapies. By combining these two therapies, it is possible to enhance the immune response against tumors, thereby improving the therapeutic efficacy for patients. Moreover, personalized target design should be emphasized to prevent tumor cell evasion caused by off-target effects. This requires in-depth understanding of the genetic and antigenic characteristics of individual patients’ tumors to ensure precise targeting. Notably, several emerging therapies are currently under development. For instance, cytokine-induced killer cell (CIK) therapy and NK cell therapy hold great promise in the field of HCC therapy. These novel therapies are being explored to provide more effective therapies for patients with HCC with advanced metastasis [183, 184]. Targeting immunosuppressive cells Both ICI and ACT therapy mainly target T cells and NK cells. Targeting immunosuppressive cells represented by TAMs in the TIME can also effectively remodel the immunosuppressive microenvironment and improve therapeutic efficacy in patients with metastatic HCC. For instance, colony-stimulating factor 1 receptor (CSF1R) serves as a crucial receptor in the transformation of macrophages from M1 to M2. It frequently binds to colony-stimulating factor 1 (CSF-1) secreted by tumor cells, thereby inducing functional alterations in itself. Significantly, TAMs typically exert their immunosuppressive functions via the CSF1–CSF1R signaling pathway [185]. Thus, blocking the CSF1–CSF1R signaling pathway represents a viable strategy for ameliorating the local immunosuppressive microenvironment, ultimately enhancing the therapeutic efficacy for patients with metastatic HCC [186]. At present, CSF1R inhibitors have advanced to the clinical trial phase. When combined with ICIs, they have brought benefits to some patients and emerged as an important therapy in the neoadjuvant treatment of HCC [187]. In addition, the CD47–SIRPα signaling axis represents a pivotal pathway through which TAMs facilitate the immune evasion of tumor cells. Tumor cells secrete CD47, which binds to SIRPα on macrophages. This not only enables tumor cells to evade macrophage phagocytosis but also promotes the transformation of macrophages into TAMs. Intriguingly, interfering with the CD47–SIRPα signaling axis has been indicated to inhibit the metastasis of HCC [188]. Overall, the CD47–SIRPα signaling axis serves as a central bridge linking tumor cells and TAMs [189]. Hence, blocking the CD47–SIRPα signaling axis can disrupt the crosstalk between tumor cells and TAMs, thereby reversing the immunosuppression associated with this crosstalk. Notably, the efficacy of SIRPα inhibitors has been initially validated in murine models of HCC. Silencing SIRPα can decrease the expression of PD-L1 on TAMs and reverse their immunosuppressive functions. In the future, SIRPα inhibitors are anticipated to emerge as a novel therapy for patients with metastatic HCC. When combined with ICIs, it will bring benefits to a larger number of patients (Fig. 6) [79]. Besides TAMs, MDSCs also play a critical role in the immunosuppressive microenvironment. It has been demonstrated that the attenuation of their immunosuppressive functions can be achieved by reducing the generation, recruitment, and accumulation of MDSCs, thereby ameliorating the local TIME. In advanced HCC, tumor cells secrete C–C chemokine receptor type 2 (CCR2) to mediate the aggregation of MDSCs to the TIME. In a murine model of HCC, it has been verified that decreasing the expression of CCR2 can reduce the degree of MDSC infiltration at the TIME and simultaneously attenuate the immunosuppressive functions of MDSCs [190]. Moreover, another study has indicated that MDSCs exert immunosuppressive functions locally through the IL-8–CXCR2 pathway, thereby reducing the efficacy of ICI therapy. Blocking the IL-8–CXCR2 pathway can effectively reverse the associated immunosuppressive effects. At present, the CXCR2 antagonist (AZD5069) has been validated for its therapeutic effects in animal models and has advanced to relevant clinical trials (Fig. 6) [191]. Besides reducing the local infiltration of MDSCs, their immunosuppressive functions can also be attenuated by targeting their metabolic pathways. Arg-1, a pivotal enzyme through which MDSCs deplete arginine in the microenvironment, has been evidenced to be significantly upregulated in the blood of patients with HCC [192]. MDSCs exert their immunosuppressive effects by depleting arginine, thereby inhibiting the proliferation of CD8+ T cells. Consequently, blocking Arg-1 can reverse the immunosuppressive effects induced by MDSCs [193]. At present, Arg-1 inhibitors have achieved a certain degree of therapeutic efficacy in clinical practice and have demonstrated great potential in combination therapies. Tumor vaccines and oncolytic viruses With the advancement of tumor immunotherapy, novel neoadjuvant approaches, including tumor vaccines and oncolytic viruses, have gradually entered clinical trials. Tumor vaccines can specifically prime immune cells to selectively eliminate tumor cells [194]. Currently, the most efficacious option is the DC vaccine. This approach involves isolating DCs from patients’ bodies and inducing their maturation. This process enables the DCs to efficiently activate T cells, thereby facilitating the elimination of tumors. Noteworthy, significant therapeutic effects have been achieved in murine models of HCC (Fig. 6) [195]. At present, during the early phase of clinical trials, safety validation has been accomplished. Considering that antigen selection necessitates individualized customization, the stability of its therapeutic efficacy is anticipated to be further enhanced in the future. Oncolytic viruses can exert their antitumor effects by either directly lysing tumor cells or inducing immunogenic cell death (ICD) of tumor cells. Additionally, they can convert “cold” tumors into “hot” tumors by reversing the immunosuppressive microenvironment [196]. JX-594, the most comprehensively investigated oncolytic virus to date, has been verified as safe and reliable in early stage clinical trials when delivered via hepatic artery infusion. Despite demonstrating antitumor activity and conferring survival benefits to certain patients, a relatively substantial proportion of patients still encounter adverse events. Its role in combination with immunotherapy remains to be further explored (Fig. 6) [197]. In the future, the determination of optimal administration routes and the thorough validation of safety for oncolytic viruses remain formidable challenges. Specifically, the complex physiological responses within the human body upon exposure to oncolytic viruses present multiple hurdles. The antibodies generated by the host’s immune system in response to the virus can potentially neutralize the virus, thereby attenuating its ability to target and eliminate tumor cells, thus undermining the expected therapeutic efficacy. Consequently, to fully harness the potential of oncolytic viruses, it is imperative to integrate them with other immunotherapeutic modalities. Such combinatorial strategies are envisioned to create synergistic effects, enhancing the overall antitumor immune response and ultimately maximizing the therapeutic benefits for patients with metastatic HCC [198]. Patient stratification and biomarkers Metastatic HCC is characterized by an extremely heterogeneous TIME and highly individualized metastatic patterns, resulting in substantial interpatient clinical heterogeneity. This heterogeneity complicates uniform treatment delivery and impairs the efficacy of routine systemic therapies, highlighting accurate TIME-based patient stratification as a critical clinical challenge in precision HCC management. The core goal of stratification is to identify robust, metastasis-specific biomarkers paired with distinct TIME signatures to guide individualized therapeutic planning and optimize clinical outcomes for metastatic HCC populations [199–201]. Table 3 comprehensively summarizes recently reported metastasis-related biomarkers, encompassing circulating proteins, tumor-specific RNA, and immune markers linked to TIME status [200, 202]. However, current evidence is largely derived from retrospective single-center analyses, lacking large-scale prospective validation. Uniformly standardized cutoff values, unified detection standard operating procedures (SOPs), and longitudinal monitoring validity of these biomarkers remain undefined. Moreover, direct comparative evaluations of the diagnostic performance, cost-effectiveness, and anti-interference capacity between TIME-derived biomarkers and conventional metastatic markers are still limited, hindering their widespread clinical application across different medical centers [199]. In the future, integrated high-risk TIME immune signatures and combined biomarker panels enable baseline stratification of patients with advanced HCC. Those with immune-exhausted TIME and elevated metastatic biomarkers should be classified as high-risk for progressive metastasis and prioritized for upfront combination systemic therapy over single-agent targeted treatment. For instance, in sorafenib-resistant HCC, leukemia inhibitory factor (LIF) derived from M2-type macrophages can inhibit the activity and cytotoxicity of NK cells, thereby promoting distant metastasis. Accordingly, elevated LIF levels may indicate that clinicians should prioritize immunotherapy over conventional targeted therapy in treatment decision-making [203]. In addition, dynamic longitudinal monitoring of core biomarkers combined with serial TIME immune phenotyping enables rational therapeutic sequencing. Patients with rising biomarker levels and persistent immune suppression after first-line targeted therapy can be timely switched to ICI-based combination immunotherapy to remodel cold TIME and inhibit distant metastasis progression [204]. Moreover, it is essential to further identify time-matched, organ-specific biomarkers that enable precise prediction of individual metastatic tropism, thereby facilitating site-targeted imaging surveillance and early intervention of invisible micrometastases during routine follow-up.Table 3Biomarkers for HCC predicting metastasisBiomarkerFunctionReferenceKRT19Predicting IM[207]HOXB5Predicting all HCC metastasis types[78]SLAMF7Predicting immunotherapy response and HCC metastasis[208]TP53Predicting microvascular invasion[209]DEUP1 promoter methylationPredicting HCC lymph node metastasis[210]ASS1 promoter methylationPredicting HCC migratory potential[211]APC promoter methylationPredicting HCC lymph node metastasis[212]MT1M promoter methylationPredicting vascular invasion[213]MT1G promoter methylationPredicting vascular invasion[213]SORT1Predicting vascular invasion[214]KDM5CPredicting HCC distant metastasis[215]JARID1BPredicting HCC distant metastasis[215]RPL6Predicting HCC lung metastasis[216]CTGFPredicting HCC invasion[217]TCF3Predicting HCC invasion and metastasis[218]GCDHPredicting HCC metastasis and prognosis[219]SAE1Predicting HCC migration and invasion[220]DLATPredicting HCC progression and metastasis[130]EMP2Predicting HCC invasion and metastasis[221]TRIM6Predicting HCC invasion and metastasis[222]MNDAPredicting M2 macrophage polarization and HCC metastasis[204]LIFPredicting NK cell activity and HCC metastasis[203]HMGB2Predicting HCC progression, metastasis, and immunosuppression[156]CDAPredicting HCC invasion and metastasis[223]PPM1GPredicting HCC metastasis[224]PDE7BPredicting HCC invasion and metastasis[139]KIAA1429Predicting HCC metastasis[225]AIFM2Predicting HCC metastasis[226]PLOD2Predicting HCC migration and invasion[227]CADPredicting HCC metastasis and progression[228]GP73Predicting HCC progression and metastasis[229]CPEB2Predicting HCC metastasis[230]SAA1Predicting HCC metastasis[231]NSUN5Predicting EMT and HCC metastasis[137]ETV4Predicting immunotherapy response and HCC metastasis[232] Table 3Biomarkers for HCC predicting metastasisBiomarkerFunctionReferenceKRT19Predicting IM[207]HOXB5Predicting all HCC metastasis types[78]SLAMF7Predicting immunotherapy response and HCC metastasis[208]TP53Predicting microvascular invasion[209]DEUP1 promoter methylationPredicting HCC lymph node metastasis[210]ASS1 promoter methylationPredicting HCC migratory potential[211]APC promoter methylationPredicting HCC lymph node metastasis[212]MT1M promoter methylationPredicting vascular invasion[213]MT1G promoter methylationPredicting vascular invasion[213]SORT1Predicting vascular invasion[214]KDM5CPredicting HCC distant metastasis[215]JARID1BPredicting HCC distant metastasis[215]RPL6Predicting HCC lung metastasis[216]CTGFPredicting HCC invasion[217]TCF3Predicting HCC invasion and metastasis[218]GCDHPredicting HCC metastasis and prognosis[219]SAE1Predicting HCC migration and invasion[220]DLATPredicting HCC progression and metastasis[130]EMP2Predicting HCC invasion and metastasis[221]TRIM6Predicting HCC invasion and metastasis[222]MNDAPredicting M2 macrophage polarization and HCC metastasis[204]LIFPredicting NK cell activity and HCC metastasis[203]HMGB2Predicting HCC progression, metastasis, and immunosuppression[156]CDAPredicting HCC invasion and metastasis[223]PPM1GPredicting HCC metastasis[224]PDE7BPredicting HCC invasion and metastasis[139]KIAA1429Predicting HCC metastasis[225]AIFM2Predicting HCC metastasis[226]PLOD2Predicting HCC migration and invasion[227]CADPredicting HCC metastasis and progression[228]GP73Predicting HCC progression and metastasis[229]CPEB2Predicting HCC metastasis[230]SAA1Predicting HCC metastasis[231]NSUN5Predicting EMT and HCC metastasis[137]ETV4Predicting immunotherapy response and HCC metastasis[232] Biomarkers for HCC predicting metastasis Notably, single biomarker and conventional TIME assessments encounter massive translational barriers, including limited sensitivity, poor cross-center reproducibility, and susceptibility to interference from underlying hepatic inflammation and cirrhosis. Integrating spatial immune, transcriptomic, and peripheral proteomic data enables the development of multi-index biomarker panels to overcome the limitations of single-marker detection. Artificial intelligence-driven modeling can further refine TIME-based predictive algorithms and optimize threshold settings, improving stratification reliability. Additionally, prospective multicenter designs with unified inclusion criteria and standardized immune detection workflows are required to validate model performance across diverse age ranges, liver function statuses, and etiological backgrounds. Such standardized frameworks will greatly enhance the reproducibility and clinical practicability of TIME-related biomarkers [205, 206]. Conclusions and perspectives Owing to its unique histological characteristics, HCC is prone to metastasis. Patients with metastatic HCC frequently lose the opportunity for surgical intervention due to deteriorated liver function. Therefore, immunotherapy dominated by ICIs has become the first-line treatment for patients with advanced metastatic HCC [16]. Our review explores immunological malignant events in the HCC metastatic cascade and summarizes the core regulatory roles of immune cells. Immunosuppressive cells, including TAMs, TANs, MDSCs, and Tregs, establish an immunosuppressive microenvironment, which drives HCC metastasis and forms a metastasis-permissive niche. Subsequently, it further elucidates the mechanisms by which immune cells promote HCC metastasis and analyzes their synergistic effects. Reversing the immunosuppressive microenvironment is therefore a key strategy to inhibit HCC metastasis. It also summarizes how tumor cells participate in immune responses and achieve immune evasion during metastasis, revealing their adaptability in the metastatic process. Furthermore, it outlines targeted therapeutic strategies to guide clinical treatment for metastatic HCC and compiles novel metastasis-related biomarkers to support patient stratified management. Notably, our review cites findings from HCC mouse models to illustrate immune cell-driven metastatic mechanisms, which still have limitations. Chemically induced mouse models poorly recapitulate human HCC with viral hepatitis and cirrhotic immune backgrounds. Given their mouse-derived stromal cells, blood vessels, and ECM, these models differ greatly from the complex, heterogeneous immune microenvironment of human tumors. In addition, their metastatic progression is abnormally accelerated and fails to fully mimic the “seed and soil” theory and organ specificity of human metastasis [233, 234], posing challenges to clinical translation. Future studies should develop more refined humanized mouse models and adopt combined multimodel strategies to comprehensively dissect metastatic mechanisms. Interestingly, our review identifies conflicting findings in existing studies. HDAC11 facilitates HCC proliferation but unexpectedly suppresses HCC metastasis, challenging the conventional view that proliferation‑promoting factors invariably drive metastasis. This offers implications for future research to break inherent perceptions and interpret results rationally. Furthermore, conflicting conclusions require further clinical validation to clarify the underlying molecular mechanisms [132]. While immunotherapy has ushered in a new era for HCC treatment, it only benefits a limited patient population for multiple reasons. Firstly, high HCC heterogeneity leads to marked interpatient differences in immunotherapeutic responses. The immunosuppressive microenvironment also impairs treatment efficacy and induces secondary resistance. In addition, HCC displays diverse metastatic patterns, and the immunological features of different metastatic lesions remain poorly characterized, hindering the development of lesion-targeted immunotherapies. Secondly, immune-related adverse events (irAEs) frequently occur during treatment, yet reliable monitoring approaches and underlying irAE mechanisms remain insufficiently elucidated [235]. Thirdly, the lack of validated biomarkers for predicting immunotherapy efficacy makes it difficult to guide therapeutic adjustment. Although ICIs, as the mainstay of HCC immunotherapy, have achieved remarkable progress in first-line treatment, acquired resistance necessitates combination with other neoadjuvant strategies. Current immunotherapies primarily aim to restore the tumor-killing function of exhausted CD8+ T cells and NK cells, while largely ignoring other immunosuppressive cells such as MDSCs, TAMs, and TANs within the TIME, which substantially contributes to inconsistent immunotherapeutic outcomes. In future studies, it is critical to block the prometastatic effect of the immunosuppressive microenvironment and clarify how immune microenvironment heterogeneity guides treatment selection and sequence for metastatic HCC. Importantly, the immune microenvironment should be recognized as a dynamic integral entity. Novel combination immunotherapies need to be developed to target multiple immunosuppressive cells and key pathways, so as to maximize efficacy while minimizing irAEs. With the progress of multiomics technologies, scRNA-seq and spatial transcriptomics can be applied to further characterize the HCC metastatic microenvironment, providing better evidence for clinical medication. Moreover, it is necessary to identify predictive biomarkers beyond PD-L1, enabling precise evaluation of immunotherapy, especially ICI efficacy and timely optimization of treatment regimens. Additionally, more attention should be paid to the influence of immunotherapy on distinct HCC metastatic patterns. For instance, assessing changes in PVTT and intrahepatic metastatic lesions before and after treatment helps clarify the specific impact of immunotherapy on HCC metastasis. These challenges require joint efforts from researchers and clinicians. In the precision medicine era, individualized therapy has become a prevailing trend. It is expected that HCC immunotherapy will soon offer new prospects for more patients with metastatic HCC [236].